SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions September class, title,number 09/06

20060210474 - Cytotoxicity mediation of cells evidencing surface expression of cd63: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The...

20060210475 - Humanized l243 antibodies: Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapuetic and diagnostic, as well as research-related uses for such antibodies, are provided....

20060210473 - Vegf-conjugate combined methods for tumor vasculature targeting and tumor treatment: The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example,...

20060210476 - Metabonomics homogeneity analysis: A metabonomic method of selecting one or more non-human primate subjects for inclusion in a study is disclosed. The method generally involves spectroscopically profiling a sample of bodily fluid acquired from a subject proposed to be included in the study. The subject is accepted or rejected as a member of...

20060210477 - Therapeutic agent for cancer: There is provided a therapeutic agent for cancer mainly comprising a saccharide having an α1→3 steric structure where an action of NKT cells on NKR-P1 (natural killer receptor P1) which is a natural killer (NK) cell antigen receptor of NKT cells in an activating ability of natural killer T (NKT)...

20060210478 - Steady state perfusion methods: Methods for assessing ischemic coronary artery disease are provided. The methods include administering a contrast agent that binds to a serum protein component to an animal and obtaining an MR image of the animal's myocardium during a period when the animal is experiencing hyperemia....

20060210479 - Targeting chelants and chelates: Novel chelants and other compounds, and compositions thereof are provided, that are useful for detection and treatment of cancer and other abnormal and disease-state cells and tissues....

20060210480 - Treatment of reduction of dysphagia: The present invention provides methods of treating or reducing dysphagia in patients. In one aspect of the invention, such method comprises administering to a patient in need of such treatment or reduction an amount of an agent sufficient to produce a therapeutically effective aversive taste response. In other aspects, such...

20060210484 - Buccal, polar and non-polar spray containing testosterone: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide testosterone for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, testosterone or a pharmaceutically acceptable ester thereof,...

20060210482 - Chemical composition and method for cold and sinus relief: A chemical composition and method for treatment of the common cold, sinusitis and other conditions associated with nasal congestion is provided. The chemical composition is made of predetermined concentrations of thymol, alcohol, eucalyptol, menthol, methyl salicylate, a preservative, saline solution and a buffer. The method includes the step of administering...

20060210481 - Medicament dispenser: A component of a medicament dispenser has a surface which, in use of the dispenser, contacts a medicinal formulation contained in the dispenser, said surface being presented by a fluorinated polymeric composition having CF3CHFCF3 as a monomer thereof....

20060210483 - Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections: A method of treatment and prevention of upper respiratory illnesses by airborne administration to a subject in need of such treatment a composition containing a therapeutically effective amount of a non-systemic antibiotic....

20060210485 - Pharmaceutical formulations: The invention relates to the use of calcium stearate to inhibit or reduce chemical interaction between an active ingredient substance and a carrier in a solid pharmaceutical formulation, wherein the active ingredient substance is susceptible to chemical interaction with the carrier. An inhalable solid pharmaceutical formulation comprising (a) an active...

20060210486 - Aerosol antiperspirant with polyamide: An aerosol antiperspirant/deodorant comprising: (a) a solvent system for the gellant in an amount of up to 36% of the total formula; (b) from 0.1-1.5% by weight based on the total weight of the composition of at least one siliconized polyamide as a gellant; (c) an antiperspirant active used in...

20060210487 - Hair wax products containing waxes, non-volatile oils and volatile hydrophobic materials: The wax product for treating or setting up a hairstyle or hairdo includes a composition containing at least one wax or wax-like substance, at least one non-volatile liquid hydrophobic oil and at least one volatile or easily volatilized hydrophobic substance that is a liquid or gas at room temperature. Because...

20060210489 - Antibacterial 3',5-disubstituted 2,4'-dihydroxybiphenyl compounds, derivatives and related methods: In the structure, R1 and R2 are independently a hydrogen atom or a lower C1-4 alkyl group and R3 and R4 are independently an alkenyl or alkyl group having from 1 to 20 carbon atoms, with the proviso that R3 and R4 are not both 2-propenyl or n-propyl when R1...

20060210490 - Confection for teeth whitening and oral hygiene: Confections for teeth whitening and oral hygiene that comprise a first component including a first bulking agent, an organic acid, and a peroxide, and a second component including a white pigment dissolved in an alkaline solution and combined with a second bulking agent. The first component forms hydrogen peroxide, a...

20060210488 - Teeth whitening candy with tartar removal and breath freshening properties: This invention discloses a teeth whitening candy intended to fill the gap between daily brushing and the need to augment dental hygiene between visits with dental professionals. The candy will enhance the removal of the tartar and plaque, which accumulates after meals. In addition to whitening teeth, the candy will...

20060210491 - Flavoured mouth wash composition: The present invention provides a flavoured product comprising four or more flavour materials having antimicrobial properties and selected from the group comprising nonanol, decanol, nonanal, decanal, amyl propionate, anethole synthetic, anisic aldehyde, basil oil, benzyl benzoate, benzyl butyrate, benzyl formate, camomile oil, cinnamic aldehyde, cis-3-hexenol, clove bud oil, damascone, ethyl...

20060210492 - Use of rifaximin for treatment and prevention of periodontal conditions: An oral preparation used for treatment and prevention of bacterial periodontal conditions consisting of a non-systemic antibiotic; and a method of treatment of periodontal conditions by orally administering to a subject in need of such treatment a composition containing a therapeutically effective amount of rifaximin....

20060210493 - Dental products comprising bone growth enhancing peptide: Dental products such as toothpastes, mouthwash and dental floss are disclosed which products are enhanced by having dissolved, dispersed or coated thereon a compound which promoted bone growth. Preferred compounds are peptide sequences comprising 10 to 50 amino acids are disclosed. The sequences are characterized by containing an integrin binding...

20060210494 - Functionally graded biocompatible coating and coated implant: The present invention provides a biocompatible coating comprising calcium phosphate that is functionally graded across the thickness of the coating. The coating, which preferably includes hydroxyapatite, is particularly useful for coating implants, such as dental or orthopedic implants. The functionally graded coating is generally crystalline near the interface with the...

20060210496 - Compositions for skin protection from ultraviolet damage: A composition for skin protection from ultraviolet damage and for application to skin or hair, including partially hydrolyzed fucoidan, a base, and a radiation protecting agent. The partially hydrolyzed fucoidan may be fucoidan derived from Tongan limu moui seaweed, Japanese kombu seaweed, Japanese mozuku seaweed, or combinations thereof....

20060210495 - Surface-modified zinc oxides: Surface-modified zinc oxides with a BET surface area of 18±5 m2/g and a C content of 0.1 to 5.0 wt. % are prepared by spraying the zinc oxides with the surface-modifying agent or adding this in vapour form and then heat-treating the mixture. They can be employed for the preparation...

20060210499 - Mild bleaching agents with increased lightening power: Bleaching agents for keratin-containing fibers, in particular, human hair, comprising (a) at least one peroxo compound and/or at least one alkalinizing agent chosen from ammonium, alkali metal and alkaline earth metal carbonates, hydrogencarbonates and carbamides (b) hydrogen peroxide, and (c) SiO2 compounds, where the last-mentioned compounds may be optionally hydrated....

20060210497 - Novel resorcinol derivatives: R1 and/or R2 represents hydrogen (H), linear or branched, cyclic or acyclic, saturated or unsaturated C1-C12 alkyl, alkenyl, cycloalkyl, or cycloalkenyl group; n represents 0, 1. When n=0, the ring is a cyclopentyl with or without one heteroatom from O, N or S and/or with or without one double bond....

20060210498 - Novel resorcinol derivatives for skin: R1 represents hydrogen (H), linear or branched, cyclic or acyclic, saturated or unsaturated C1-C12 alkyl, alkenyl, cycloalkyl, or cycloalkenyl group. Preferably, R1 represents hydrogen (H) or a C1 alkyl group (i.e, methyl group). More preferably, R1 represents hydrogen; n represents 0, 1. When n=0, the ring is a cyclopentyl with...

20060210501 - Color cosmetic comprising yerba santa extract: The application discloses and claims a color cosmetic composition providing moisturization, hydration, and lubrication through the use of Yerba Santa fluid extract. Specific formulations for anti shine pressed powder, blush, brow wax, concealer, eye shadow, lipstick and gloss, mascara, shimmer shadow and foundation compositions are disclosed....

20060210500 - Formulations: The present invention relates to formulations for topical applications comprising pigments obtainable by agitating a suspension comprising one or more inorganic pigments and silver oxide, in order to reduce undesirable side effects caused by microorganisms....

20060210502 - Anhydrous antiperspirant composition containing skin softeners: Disclosed is an anhydrous topical antiperspirant composition comprising a dermatologically acceptable carrier and a perspiration reducing effective amount of a particulate antiperspirant salt suspended in the carrier. In addition, the composition includes behenoxy dimethicone and a non-polar, non-volatile liquid emollient oil. Such a composition provides improved skin feel (i.e. softer...

20060210503 - Aromachemicals: R and R1 are each independently H or C1-5 alkyl provided that in formula (I) when R is methyl, R1 is H or C2-5 alkyl. R2 has from 1 to about 12 carbon atoms and is a straight or branched aliphatic group, or a cyclic, heterocyclic or aromatic group. R3...

20060210504 - Compositions and methods for inhibiting eccrine perspiration in humans: Non-pathological, physiologically normal sweating is inhibited through use of an a muscarinic anticholinergic amine that blocks parasympathetic stimuli from cholinergic nerve fibers to an innerved sweat gland. The anticholinergic agent is included in a form adapted to be topically applied to commonly sweaty areas of the body. Side effects are...

20060210505 - Multi-phase personal care composition comprising visually distinct phases: Multi-phase personal care compositions comprise a first phase and a second phase, wherein said first and second phases form a visually distinct pattern. The compositions are intended for moisturizing or conditioning skin or hair and comprise less than about 10%, by weight of the multi-phase personal care composition, of surfactant....

20060210508 - Fragrance delivery system for surface cleaners and conditioners: We claim a fragrance delivery system consisting of a mixture of various polymers oligomers and stabilizers capable of forming a surfactant complex gel dispersion when combined with a cleansing surfactant base and yielding high levels of fragrance deposition onto the skin, hair or other surface such as a textile, from...

20060210509 - Hair conditioner: The present invention generally relates to a silicone-based hair conditioning composition having improved silicone hair conditioner deposition upon the hair. The composition of the invention comprises hair conditioning compositions having dispersed, non-volatile silicone conditioning agents, cationic conditioning agents and at least one nonionic amphiphilic polymer having at least one fatty...

20060210516 - Article with skin protecting and moisturizing compound: An article with skin-protecting and moisturizing compound, comprising a tissue substrate, a base and partially hydrolyzed fucoidan. The partially hydrolyzed fucoidan may be sulfonated. The partially hydrolyzed fucoidan may be derived from Tongan limu moui seaweed, Japanese wakame seaweed, Japanese mozuku seaweed, or combinations thereof....

20060210518 - Composition containing a urea compound and an oxyalkylenated compound: in which: R1, R2, R3 and R4 represent, independently of each another, a hydrogen atom, a C1-C4 alkyl group or a C2-C6 hydroxyalkyl group possibly containing from 1 to 5 hydroxyl groups, in which at least one of the radicals R1 to R4 represents a hydroxyalkyl group, and also the...

20060210519 - Exfoliating and moisturizing composition and method: An exfoliating and moisturizing composition for the skin includes a wax component having a melting point of at least 35° C. and an exfoliant mineral component dispersed in the wax component. The mineral component has a particle size of no more than 3 microns. Minerals may include a clay and/or...

20060210515 - Hair growth formula: A hair treatment composition for topical application to the skin and/or hair, comprising partially hydrolyzed fucoidan and a pharmaceutical carrier. The composition may contain further additives. The carrier may be hydrophyllic or anhydrous. The composition may also include natural components such as honey and/or mangosteen. The composition may also include...

20060210513 - Method of using skin compositions including tensioning polymers: The invention features a method of treating at least one sign of aging on the skin selected from the group consisting of (i) thickening the skin, (ii) enhancing the barrier function of skin, and/or (iii) treating at least one sign of aging on the skin selected from the group consisting...

20060210511 - Methods of treating skin and mucosal tissue atrophy using compositions including tensioning polymers: The present invention features a method of treating atrophy of skin or mucosal tissue by administering to skin or mucosal tissue in need of such treatment a composition including a tensioning polymer, said method selected from the group consisting of thickening said skin or mucosal tissue, enhancing extracellular matrix production...

20060210510 - Nucleic acid molecules coding for a dextran-saccharase catalysing the synthesis of dextran with alpha 1,2 osidic sidechains: The invention relates to an isolated polypeptide with an glycosyl transferase enzymatic activity for producing dextrans with α(1→2) sidechains, comprising at least one region for bonding to glucan and a catalytically active region situated beyond the region bonding to glucan. The invention further relates to polynucleotides coding for said enzymes...

20060210517 - Skin cleansing article: A skin care article including a carrier and a moist application that includes partially hydrolyzed fucoidan. The partially hydrolyzed fucoidan may by sulfonated. The present invention also discloses a method of making a skin care article by partially hydrolyzing fucoidan, mixing it with a base and applying it to a...

20060210512 - Skin compositions including tensioning polymers: The invention features an emulsion composition including (i) at least about 35% by weight water and (ii) at least about 2% by weight of at least one tensioning polymer having a contractile force greater than about 3 grams/milligram and a water-resistance index from about 0.9 to about 1.9....

20060210514 - Skin protection and moisturizing compositions and method of making the same: Compositions and methods relating to partially hydrolyzed fucoidan for use in skin care compositions are described. Fucoidan from brown seaweeds is partially hydrolyzed and then mixed with other ingredients for use as a skin care composition in cream, lotion, ointment, or other form. The fucoidan is partially hydrolyzed with acid...

20060210520 - Macadamia lipid based surfactants and derivatives and process for preparing same: Novel macadamia-lipid based esters, derivatives, surfactants and emollients are disclosed, as well as their use in the production of surface active derivatives or non-surface active esters and ester emollients. The esters, surfactants and fatty derivatives are useful as emollients, dispersants, emulsifiers, and conditioners for hair care and skin care products....

20060210521 - Composition containing a urea compound and an alkyl glycol carboxylate compound: v

20060210522 - Lipid composition and skin care formulation containing the same:

20060210507 - Cosmetic composition comprising at least one sulphonic polyester and at least one polyurethane: Disclosed herein is a cosmetic composition comprising, in a cosmetically acceptable medium, at least one water-dispersible sulphonic polyester and at least one high molecular weight polyurethane. Also disclosed herein is a method for shaping, fixing, and/or holding the hair comprising applying this cosmetic composition to the hair....

20060210506 - Organopolysiloxane hair treatment agent and hair cosmetic containing the treatment agent: s

20060210523 - Compositions of marine botanicals to provide nutrition to aging and environmentally damaged skin: The present invention relates to novel methods and compositions comprising marine botanicals for treating aged, mature, nutritionally-compromised, or environmentally-damaged skin. These methods and compositions provide improvements in the skin's visual appearance, physiological functions, clinical properties, and biophysical properties....

20060210524 - Skin care composition: Skin care compositions for the care of wrinkles including partially hydrolyzed fucoidan, a base, and an anti-wrinkle compound. The partially hydrolyzed fucoidan may be sulfonated. The partially hydrolyzed fucoidan may be derived from Japanese mozuku seaweed, Japanese kombu seaweed, or Tongan limu moui seaweed. Also disclosed is a method of...

20060210525 - Dispersions: The invention relates to new dispersions, especially for underwater paints, containing (a) a microencapsulated anti-fouling component and (b) an organic solvent....

20060210526 - Conjugated biological molecules and their preparation: Novel biologically active compounds of the general formula (I) in which one of X and X′ represents a polymer, and the other represents a hydrogen atom; each Q independently represents a linking group; W represents an electron-withdrawing moiety or a moiety preparable by reduction of an electron-withdrawing moiety; or, if...

20060210527 - Cyclodextrin-based polymers for therapeutics delivery: The present invention relates to novel compositions of therapeutic polymeric compounds designed as carriers for small molecule therapeutics delivery and pharmaceutical compositions thereof. In some embodiments, the small molecule therapeutic is attached to the polymer by a photocleavable linker. The polymeric compounds may also employ targeting agents. By selecting from...

20060210529 - Method of attenuating neurogenic bruise formation: The present invention provides a method of attenuating the formation or reducing the severity of a neurogenic bruise in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount...

20060210528 - Therapy for tropical diseases: Disclosed are methods and formulations for the treatment of topical conditions on mammalian tissues such as skin and mucous tissues mediated at least -in part by viral, bacterial or fungal infections in the mammal. The methods of this invention involve the in situ formation of a polymeric film over the...

20060210530 - Polymer coating of cells: Polymers and methods of making them are described. The polymers may be used to coat living cells. The polymer-coated cells are useful in cell therapy applications....

20060210531 - Agent eleveting dendritic cell precursor level in blood: Although the fields of therapeutic applications of dendritic cells are now expanding, dendritic cell precursors exist only in a small amount in the peripheral blood and, therefore, it is still difficult to obtain them in a therapeutically useful amount even though they are proliferated in vitro. Therefore, it is a...

20060210532 - Means and methods for the recruitment and identification of stem cells: Described are methods of modulating stem/progenitor cell recruitment involving molecules that agonize the formation of plasmin stimulating the recruitment of stem/progenitor cells, including hematopoietic and endothelial precursor cells. Conversely, antagonists of plasmin can inhibit recruitment of the stem cells. In addition, the identification of the uPA receptor (uPAR) as a...

20060210533 - Compounds and compositions for delivering active agents: Oxadiazole compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well....

20060210534 - Pegylated interleukin-10: Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus...

20060210539 - Anti-angiogenic methods and compositions: Disclosed herein are methods and compositions for treatment of conditions requiring inhibition of angiogenesis. Such conditions include those characterized by neovascularization, such as retinopathies, macular degeneration and various malignancies....

20060210540 - Compositions and methods for enhancing the immunogenicity of antigens: The present invention provides recombinant polypeptides comprising an N-terminal fragment of an ActA protein or LLO protein fused to an antigen or a fragment thereof, nucleotides encoding same, recombinant vectors comprising same, and immunogenic and therapeutic methods utilizing same....

20060210535 - Means for regulating the expression of human isoforms of ant: ARNi which can selectively inhibit expression of an isoform of ANT, characterized in that said ARNi are an ARN duplex, one of the strands being highly homologous to a fragment of ARNm coding for said isoform of ANT....

20060210536 - Methods and compositions for inhibiting stat signaling pathways: The invention relates to compositions and methods for modulating cell signaling mediated by signal transducers and activators of transcription (STAT). The compositions target cellular STAT3 and STAT1 protein, particularly STAT3, for degradation via the ubiquitination pathway. Thus, the STAT inhibiting agents are useful for inhibiting STAT mediated signal transduction events,...

20060210541 - Methods for treating and preventing vascular disease: Methods for treating and/or preventing vascular disease are disclosed. The methods use gene delivery techniques to deliver nucleic acid molecules encoding anti-inflammatory cytokines to a subject....

20060210537 - Theileria parva dna vaccines: The present invention relates to recombinant anti-Theileria parva vaccines and the administration of such vaccines to animals, advantageously bovines. Advantageously, the anti-Theileria parva vaccine encompasses a recombinant avipox virus that includes a nucleotide sequence encoding a Theileria parva gene. The invention further relates to methods of vaccinating animals, advantageously bovines,...

20060210538 - Use of apotosis inhibiting compounds in degenerative neurological disorders: The invention provides methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain associated with a neurodegenerative diseases that is characterized by an excess buildup of buildup of intracellular protein aggregates. In particular, the invention provides methods and compositions used...

20060210544 - Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient: Intravenous administration of bone marrow cells collected from rat bone marrow or peripheral blood to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or...

20060210545 - Process for treating spirulina: The treatment of spirulina by a process which includes placing spirulina that has not been previously heat-sterilized, lactic acid bacteria and sugar in water, then culturing the lactic acid bacteria provides treated spirulina in which the distinctive taste and odor of spirulina are minimized, in which active ingredients such as...

20060210543 - Method of treating infarcted myocardium: A method of treating an infarcted myocardium, the method comprising administering to the myocardium of a subject in need thereof a therapeutically effective amount of osmotically activated immune cells, thereby treating the infarcted myocardium....

20060210542 - Use of tpo mimetic compounds and pharmaceutical compositions in the treatment of anemia: A method of treating anemia is disclosed. The method includes administering a TPO mimetic compound to a subject. Pharmaceutical compositions including a TPO mimetic compound and a pharmaceutically acceptable carrier as well as diagnostic methods employing a labeled TPO mimetic compound are also disclosed....

20060210546 - Athlete dietary supplement: A vitamin supplement to temporarily enhance the abilities of a individual during a sport activity which includes a plurality of B family vitamins and one or more other vitamins, minerals, and/or natural ingredients....

20060210547 - Dna encoding anti-apoptotic protein and recombinant 30k protein: The present invention relates to DNAs encoding anti-apoptotic 30K proteins. More particularly, the present invention is directed to 30K protein genes and a recombinant proteins prepared by using novel anti-apoptotic gene obtained from silkworm. The present invention also provides anti-apoptotic health care food, pharmaceutical preparation, additive for cell culture medium,...

20060210549 - Controlled release liposomes and methods of use: The present invention provides liposomes that include a trigger polypeptide, a lipid layer, and a compartment surrounded by the lipid layer and methods of using the liposomes....

20060210548 - Method for reducing obstructive hydrocephalus: A process for reducing cerebrospinal fluid flow obstruction includes the administration of a therapeutic dose of a clot-reducing agent to a subject having preconditions or obstructive hydrocephalus symptoms. The dose is maintained within the subject for a period of time sufficient to reduce cerebrospinal fluid flow obstruction. The clot-reducing agent...

20060210550 - Angiogenesis inducer: It is intended to provide an angiogenesis inducer comprising fibrin which is safe to a living body. The angiogenesis inducer is characterized by being capable of safely inducing angiogenesis when administered to a living body, which makes it possible to achieve functional regeneration of living tissues or organs suffering from...

20060210552 - Compositions and methods for systemic inhibition of cartilage degradation: Methods and compositions for inhibiting articular cartilage degradation. The compositions preferably include multiple chondroprotective agents, including at least one agent that promotes cartilage anabolic activity and at least one agent that inhibits cartilage catabolism. The compositions may also include one or more pain and inflammation inhibitory agents. The compositions may...

20060210551 - Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses: The invention concerns the use of a mast cell activation- or degranulation-blocking agent in the manufacture of a medicament for preventing and treating cerebral complications caused by thrombolytic treatment. The invention also relates to treatment of patients suffering from cerebral complications associated with thrombolysis. Further, the invention provides thrombolytic compositions...

20060210553 - Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excesssive cell proliferation: The present invention relates to the use of the alkaloid K252 and its analogues or derivatives to prepare topical drugs for the treatment of disorders characterised by hyperproliferation of keratinocytes....

20060210554 - Detection of cholesterol ozonation products: The invention relates to detection of cholesterol ozonation products that are generated by atherosclerotic plaque material, and to methods of detecting vascular conditions that relate to the accumulation and oxidation of cholesterol....

20060210555 - Compositions comprising immunoreactive reagents and saponins, and methods of use thereof: The present invention relates to pharmaceutical compositions that are useful for the prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response, and methods of...

20060210556 - Novel composition and methods for the treatment of immune disorders: The present invention relates to compositions of matter and methods for the treatment and diagnosis of immune related diseases, including those mediated by cytokines released primarily either Th1 or Th2 cells in response to antigenic stimulation. The present invention further relates to methods for biasing the differentiation of T-cells in...

20060210557 - Stabilized liquid polypeptide formulations: The present invention provides formulations for maintaining the stability of polypeptides, in particular, therapeutic antigen-binding polypeptides such as antibodies and the like, for example, anti-Aβ antibodies. The formulations generally include an antioxidant in a sufficient amount as to inhibit by-product formation, for example, the formation of high molecular weight polypeptide...

20060210558 - Hematopoietic cell selectin ligand polypeptides and methods of use thereof: The invention feature methods and compositions for treating inflammatory disorders, hematopoietic disorders and non-hematopoietic disorders (e.g., non-hematopoietic cancers) and for isolating cells (e.g., stem cells) in a mammal....

20060210561 - Dosages for treatment with anti-egfr antibodies: The present invention concerns dosages for treatment of human cancer patients with an anti-Epidermal Growth Factor Receptor (EGFR) antibody....

20060210559 - Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use: Disclosed herein are nucleic acid sequences that encode polypeptides. Also disclosed are antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving...

20060210560 - Tnf receptor action modulaton: A method of modulating signal transduction and/or cleavage in Tumor Necrosis Factor Receptors (TNF-Rs) is provided. Peptides or other molecules may interact either with the receptor itself, or with effector proteins interacting with the receptor, thus modulating the normal functioning of the TNF-Rs. Such peptides or other molecules may be...

20060210563 - Administration of anti-cytokine f(ab')2 antibody fragments: The present invention is directed to a method of treating a cytokine-mediated immune reaction in a patient in need of such treatment by administration of an effective amount of anti-cytokine F(ab′)2 antibody fragments. The antibody fragments are preferably free from albumin and of whole antibodies, as well as substantially free...

20060210565 - Antagonists of hmg1 for treating inflammatory conditions: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring...

20060210566 - Methods of treating anemia by inhibition of vascular endothelial growth factor (vegf): Methods of treating anemic disorders in human subjects comprising administering a VEGF antagonist comprising a fusion polypeptide having an immunoglobulin-like (Ig) domain 2 of the VEGF receptor Flt1 and Ig domain 3 of the VEGF receptor Flk1 or Flt4, and a multimerizing component. Further included are methods of preventing anemia,...

20060210564 - Novel diabody-type bispecific antibody: The purpose of the present invention is to provide a diabody-type bispecific antibody, which is characterized by having low immunogenicity and high infiltrating activity into tumor tissues, and by being easily mass-produced at a low cost with use of microorganisms, and by being easily altered in function by means of...

20060210562 - Treatment of type 1 diabetes before and after expression of predisposition markers: The present invention relates generally to the use of compounds, compositions, combinations, kits, and methods for the effective endocytic presentation of immunosuppressive factors for the down regulation of diabetogenic T cells for the treatment of type I diabetes....

20060210567 - Antibodies against pd-1 and uses therefor: This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders,...

20060210569 - Antibodies inhibiting transportation activity of peptide transporter: The present inventors discovered that the PepT-binding antibodies have the ability to inhibit the transport activity of peptide transporters, as a result of dedicated research. These antibodies may be utilized as cell growth inhibitors, for example, for treating and preventing cancer....

20060210571 - Engineering antibodies that bind irreversibly: The present invention provides a mutant antibody comprising a reactive site not present in the wild-type of the antibody and a complementarity-determining region that specifically binds to a metal chelate, wherein the reactive site is in a position proximate to or within the complementarity-determining region....

20060210568 - Methods and compositions for cancer treatment: Methods and compositions for breast cancer treatment and prevention by inducing overexpression of adipose differentiation related protein (ADRP) in the cancer cells. Over expression of ADRP causes breast cancer cells to re-differentiate, whereby cancer cell proliferation and tumorigenesis is inhibited and cancer cells are induced to undergo apoptosis. Also disclosed...

20060210570 - Methods and compositions for modulating prostasin: The invention provides methods and compositions related to modulating prostasin....

20060210573 - Peptide useful in immunomodulation: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to...

20060210572 - Treatment of lymphatic metastatic cancerous lesions: Methods for improving the efficacy of cancer therapy are described. In one embodiment the method involves administering the cancer therapeutic to a first cancer lesion wherein the first cancer lesion is connected through the lymphatic system to a second cancer lesion and wherein the cancer therapeutic can thereby travel to...

20060210574 - Pharmaceutical compositions and articles of manufacture useful in reversal of a clinical epiosode of an incurable disease and methods of use thereof: A method of reversing a clinical episode of a disease which is generally considered incurable in a subject. The method includes providing an immune-globulin preparation containing a detectable titre of antibodies to the disease which is generally considered incurable and administering the immune-globulin preparation to the subject. Preferably, the immune...

20060210575 - Cytotoxic protein and utilization thereof: This invention provides a cytotoxic protein (M toxin) produced by Helicobacter pylori, a partial peptide, and an antitumor agent containing the cytotoxic protein. The protein is obtained by culturing a transformant which is transformed with a recombination vector containing DNA coding the cytotoxin protein. This invention provides further the use...

20060210576 - Method for treating or preventing metastasis of colorectal cancers: Disclosed are methods of identifying agents for treating metastatic lesions of colorectal cancer. Also disclosed are methods for treating metastatic lesions of colorectal cancer and preventing metastasis of colorectal cancer....

20060210577 - Rtvp-glipr-like compositions and methods for the detection, treatment and prevention of prostate cancer: The invention is directed to purified and isolated novel RGL2 polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above....

20060210578 - Immunogenic polypeptide isolated from mycobacterium avium subspecies paratuberculosis and uses therof: The present invention relates to an immunogenic polypeptide isolated from Mycobacterium avium subspecies paratuberculosis and variants of the polypeptide. The polypeptide and variants may be used in vaccines against Johne's disease and in methods for detection of the disease. Antibodies against the polypeptide or variants may be used in diagnostic...

20060210579 - Nucleic acids and proteins from streptococcus groups a & b: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics....

20060210580 - Nucleic acids and proteins from streptococcus groups a & b: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics....

20060210581 - Nucleic acids and proteins from streptococcus groups a & b: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics....

20060210582 - Nucleic acids and proteins from streptococcus groups a & b: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics....

20060210583 - Nucleic acids encoding sarcocystis neurona antigen and uses thereof: The present invention provides novel isolated nucleic acids encoding antigenic proteins derived from Sarcocystis neurona, or unique fragments thereof. In particular, the invention provides novel isolated nucleic acids encoding membrane-associated polypeptides SnSAG2, SnSAG3, and SnSAG 4. Also provided are purified antigenic polypeptide fragments encoded by the novel nucleic acid sequences...

20060210584 - Method for preparing citrinin-free monascus biomass and use of citrinin-free monascus biomass: Disclosed is a method for preparing a citrinin-free Monascus biomass. Also disclosed are a pharmaceutical and a functional food comprising a preparation by the method. The Monascus biomass possesses anti-oxidation property, and shows anti-proliferation property on cancer cells via apoptosis pathway....

20060210585 - Method for the production of hiv-1 gag virus-like particles: The invention describes a vector including a nucleotide sequence encoding an HIV Gag polypeptide for use in the production of HIV-1 Gag virus-like particles. The vector may be a plant vector, for example, a tobacco mosaic virus vector such as the pBSG1057 vector or a tobacco etch virus vector. The...

20060210586 - Recombination bcg vaccine: A recombinant BCG vaccine being transformed with an expression vector that has a polynucleotide encoding a foreign antigenic protein, wherein the polynucleotide is a modified one in which a third position of each codon is substituted with G or C without a change of an amino acid. This recombinant BCG...

20060210587 - Virus-like particles for the induction of autoantibodies: The invention described herein relates to compositions and methods for stimulating immune responses in vivo against a tolerogen. Novel biotechnological tools, pharmaceuticals, therapeutics and prophylactics, which concern chimeric or conjugated virus-like particles, and methods of use of the foregoing are provided for the study of B cell tolerance and the...

20060210588 - Hiv-peptide-carrier-conjugates: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP which can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs), and particular HIV peptides linked thereto....

20060210589 - Methods for treating myofascial pain: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G....

20060210590 - Minor allergen control to increase safety of immunotherapy: The invention discloses a method for standardizing allergen extract with respect to the contents of major as well as minor allergens. The method comprises determining relative amounts of allergens in a given extract, followed by an adjustment of the contents of major an minor allergens so as to meet predefined...

20060210591 - Immunization of an individual against carcinomas and the preliminary stages thereof: The present invention relates to a pharmaceutical composition, comprising a cell cycle regulatory protein and/or an expressible nucleic acid coding for this in an amount suitable for immunization of an individual against carcinomas and the preliminary stages thereof and common auxiliary agents and/or to the use of a cell cycle...

20060210592 - Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis: An oral preparation consisting of a non-systemic antibiotic and a proton pump blocker used for prevention of aspiration pneumonia and sepsis; and a method of prevention of aspiration pneumonia and/or sepsis by orally administering to a subject in need of such treatment a composition containing a therapeutically effective amount of...

20060210593 - Methods of making and methods of using antiseptic disinfectant, cosmetic and toiletries, medicine or food containing the same: The present invention relates to methods for producing and using antiseptic disinfectant, cosmetic and toiletries, medicine or food and method for antiseptically disinfecting a cosmetic and toiletries, medicine or food. The cosmetic and toiletries, medicine or food contain an antiseptic disinfectant comprising 1,2-alkanediol with 5-10 carbons and a fragrance component,...

20060210594 - Composite spinal nucleus implant with water absorption and swelling capabilities: Embodiments relate to a spinal nucleus implant with water absorption and swelling capabilities, compositions for producing the spinal nucleus implants, and methods of preparing and using the spinal nucleus implants. The spinal nucleus implant can be created from a composition comprising a mixture of non-hydrogel polymer material and at least...

20060210595 - Device containing cytophilic islands that adhere cells separated by cytophobic regions: The invention provides a device for adhering cells in a specific and predetermined position, and associated methods. The device includes a plate defining a surface and a plurality of cytophilic islands that adhere cells, isolated by cytophobic regions to which cells do not adhere, contiguous with the cytophilic islands. The...

20060210599 - High viscosity liquid controlled delivery system and medical or surgical device: The present invention relates to novel nonpolymeric compounds and compositions that form liquid, high viscosity materials suitable for the delivery of biologically active substances in a controlled fashion, and for use as medical or surgical devices. The materials can optionally be diluted with a solvent to form a material of...

20060210597 - Prosthetic implants including ecm composite material: Described are preferred prosthetic valve devices including a first extracellular matrix material having a second extracellular matrix material deposited thereon. The preferred materials are made by culturing cells in contact with an extracellular matrix graft material in a fashion to cause the cells to biosynthesize and deposit extracellular matrix components...

20060210598 - Resorbable structure for treating and healing of tissue defects: Devices and processes (e.g., improved Plasticized Melt Flow processes (PMF) or improved Phase Separation Polymer Concentration (PSPC), etc.) used to make resorbable and non-resorbable structures for treating and/or healing of tissue defects are disclosed. Among the advantages of using these improved processes are the preservation of molecular weight and the...

20060210596 - Seeding implantable medical devices with cells: Apparatus and methods for seeding an implantable medical device, such as a vascular prosthesis, with cells, such as endothelial cells, are described. The invention supports techniques for seeding a luminal surface of the device with axial centrifugation. Cells are introduced in suspension into the lumen of the device. The introduction...

20060210600 - Coated stent with timed release of multiple therapeutic agents to inhibit restenosis adjacent to the stent ends: The present invention provides a system for treating a vascular condition that inhibits restenosis adjacent to the ends of a stent by delivering a therapeutic agent to the vessel wall at and beyond the stent ends. The system comprises a catheter and a coated stent operably coupled to the catheter....

20060210602 - Compositions and systems for forming crosslinked biomaterials and methods of preparation and use: Crosslinkable compositions are provided that readily crosslink in situ to provide biocompatible, nonimmunogenic crosslinked materials that may be used as adhesive compositions. The compositions comprise collagen and a plurality of crosslinkable components having reactive functional groups thereon, with the functional groups selected so as to enable inter-reaction between the components,...

20060210603 - Implantable medical articles having laminin coatings and methods of use: Laminin-containing coatings for the surfaces of implantable medical devices are disclosed. The coatings promote the formation of vessels in association with the coated surfaces with minimal fibrotic resonse....

20060210601 - Stretchable collagen material and manufacturing method and use thereof: The present invention provides a stretchable collagen material, particularly collagen derived from fishes, having excellent stretching property and mechanical strength, which can be widely used as a cell carrier and medical material, and to a method for manufacturing the same. By thermally treating a gel comprising collagen fiber cross-linked by...

20060210604 - Ocular delivery of polymeric delivery formulations: The present invention provides a flowable composition suitable for use as a controlled release implant. The flowable composition can be administered into the ocular region of a mammal. The composition includes: (a) a biodegradable, biocompatible thermoplastic polymer that is at least substantially insoluble in aqueous medium, water or body fluid;...

20060210605 - Devices, systems and methods useable for treating sinusitis: Sinusitis and other disorders of the ear, nose and throat are diagnosed and/or treated using minimally invasive approaches with flexible or rigid instruments. Various methods and devices are used for remodeling or changing the shape, size or configuration of a sinus ostium or duct or other anatomical structure in the...

20060210606 - Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood: The present invention aims at preventing or retarding a transition to hemodialysis treatment in kidney failure or decreasing the number of implementation of the hemodialysis therapy and preventing or lessening occurrence of accompanying hyperammonemia in hepatic insufficiency. To accomplish the purposes described above, the pathological improvement food of the invention...

20060210609 - Fucoidan compositions and methods for dietary and nutritional supplements: Compositions and methods relating to partially hydrolyzed fucoidan for use in dietary supplements are described. Fucoidan from brown seaweeds is partially hydrolyzed and then mixed with other ingredients for use as a dietary supplement in beverage, capsule, or tablet form. The fucoidan is partially hydrolyzed with acid and heat. The...

20060210610 - Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use: Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use are disclosed....

20060210608 - Mineral composition: The present invention relates to a mineral composition, characterized in that the mineral composition comprises 100 parts by weight of a metal salt having a solubility product in water at 25° C. of 1.0×10−7 or less and 0.5 to 50 parts by weight of an emulsifier having an HLB of...

20060210607 - Water-soluble isoflavone composition, process for producing the same, and use thereof: An isoflavone composition which contains an α-glucosyl isoflavone and isoflavone and optionally an isoflavone aglycone, wherein the ratio of the amount of aglycone in the isoflavone and the isoflavone aglycone in total to the amount of aglycone in the α-glucosyl isoflavone [(the amount of aglycone in α-glucosyl isoflavone)/(the amount of...

20060210611 - Fat soluble vitamin feed supplements and processes for delivering same: A process is disclosed for delivering a stable, fat soluble vitamin to a feed composition. The process includes dissolving a fat soluble vitamin in a solvent to form a vitamin-enriched solvent and combining the vitamin-enriched feeds; processes for supplementing the diet of a feed animal with a fat soluble vitamin,...

20060210612 - Make-up-removing article: An article containing:(A) a water-insoluble hydrophilic polyurethane foam support, and, impregnated on the support,(B) a composition containing separate, non-emulsified aqueous and oily phases, the aqueous and oily phases being present in a ratio by weight ranging from 25/75 to 90/10 (aqueous/oily), the oily phase having a melting point of less...

20060210614 - Method of treatment of a metabolic disease using intranasal administration of exendin peptide: Methods for treating metabolic diseases are described for intranasal delivery of an exenatide, comprising an aqueous mixture of exendin, and a delivery enhancer selected from the group consisting of a solubilizer, a chelator, and a surfactant, and the pharmaceutical formulations used therein....

20060210613 - Therapeutic wound care product: The present invention relates to a multi-layered product having at least one therapeutic agent therein and a layer containing a chitin or chitin derivative for treatment of a wound, and also to a method using such product....

20060210615 - Dermal or transdermal therapeutic system comprising an ormocer with barrier effect on a cover foil: The invention relates to a dermal or transdermal therapeutic system comprising a cover foil with barrier effect against gas, odour and volatile light substances. Said invention is characterised in that the cover foil is provided with at least one substrate and with at least one layer consisting of an inorganic-organic...

20060210617 - Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl: Silicone adhesive formulations are provided, in which fentanyl particles are suspended one or more a solvated silicone adhesives. The formulations can be used for manufacturing improved, matrix-type transdermal devices for administering fentanyl....

20060210616 - Therapeutic patch for ophthalmologic and cosmetic use: This invention is directed to a therapeutic patch for ophthalmologic and cosmetic use that provides therapy to the region where the patch is provided; the therapeutic patch provides a therapeutic delivery surface for placement against, for example, the eyelid and peri-orbital structures of a patient, and a non-contacting surface that...

20060210619 - Limposomes containing asiaticoside and the uses thereof: This invention belongs to the chemical field, which is related to the fields of pharmaceutical preparations and cosmetic, especially to asiaticoside-liposome and its use for preparing pharmaceutical preparations and cosmetic. In this invention, asiaticoside and lipid components are fused by heating or dissolved in organic solvents, then treated with the...

20060210618 - Phospholipid derivatives and process for the production there: wherein [PG]k represents a residue of polyglycerin having a polymerization degree of k, wherein k is 2 to 50, R1CO and R2CO independently represent an acyl group having 8 to 22 carbon atoms, symbol “a” independently represents an integer of 0 to 5, symbol “b” independently represents 0 or 1,...

20060210620 - Co-precipitated amorphous losartan and dosage forms comprising the same: The technical field of the invention relates to spray dried, co-precipitate amorphous losartan dosage forms that are stable over time and processes for their preparation. The processes stabilize the amorphous losartan. The process includes preparing an aqueous solution of losartan and one or more hydrophilic polymers; and spray drying the...

20060210621 - Solid dosage form for providing a dietary supplement: Compositions and methods relating to partially hydrolyzed fucoidan for use in dietary supplements are described. Fucoidan from brown seaweeds is partially hydrolyzed and then mixed with other ingredients for use as a dietary supplement in beverage, capsule, or tablet form. The fucoidan is partially hydrolyzed with acid and heat. The...

20060210622 - Surface modified particulate compositions of biologically active substances: This invention disclosure relates to compositions for the delivery of stable surface modified sub-micron and micron sized particles of water-insoluble biologically active substances from a non-aqueous medium that self-disperses on exposure to an aqueous environment....

20060210623 - Sustained release delivery of isradipine: Sustained release oral formulations of israpidine, methods of preparing same, and methods of using sustained release oral formulations to provide controlled delivery of israpidine. The sustained release oral formulations include israpidine and a sustained release polymer, and provide substantially zero order release of israpidine over an extended period....

20060210624 - Combination product comprising an antagonist or inverse agonist of histamine receptor h<sb>3 </sb>and an antipsychotic and antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of p: Medicament comprising, in a pharmaceutically acceptable vehicle, an anti-psychotic or an antidepressant (A), which, on its own, has an undesirable effect of a gain in body weight or sedation, and an antagonist and/or inverse agonist (B) of the histamine H3 receptor, the antagonist and/or inverse agonist of the histamine H3...

20060210627 - Direct compression formulation and process: This invention relates to tablets especially tablets formed by direct compression of a dipeptidylpeptidase IV (DPP-IV) inhibitor compound, a process for the preparation thereof, to new pharmaceutical formulations, and new tableting powders comprising DPP-IV inhibitor formulations capable of being directly compressed into tablets. The invention relates further to a process...

20060210626 - Radio frequency identification pharmaceutical tracking system and method: An ingestible dosage form includes a pill containing a pharmaceutical content and an RF tag associated with the pill. The RF tag is configured to output a wireless response signal in response to a wireless excitation signal received by the RF tag from an RF reader. The ingestible dosage form...

20060210625 - Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms: An oral pharmaceutical composition, comprising one or more positively charged, highly water-soluble pharmaceutically active agents such as trospium chloride, and one or more polymers containing polarized oxygen atoms, whereby the active agent(s) form an ion-dipole interaction with the polymer(s) that may be used for an immediate release system, an extended...

20060210628 - Use of epinine for enhancing physical performance: A method of decreasing fat and adipose tissue, and increasing alertness in humans comprises administering epinine in a daily dosage between about 50 and 300 mg. Epinine may be administered once per day or in multiple doses, either alone or in combination with other compounds and mixtures....

20060210630 - Controlled release compositions of gamma-hydroxybutyrate: The present invention is directed to oral pulse-release pharmaceutical dosage form containing an immediate release component of gamma-hydroxybutyric acid, and one or more delayed/controlled release components of gamma-hydroxybutyric acid....

20060210629 - Zinc-containing sustained-release composition, its preparation, and method for producing the same: With a simple and high-yield production method, a zinc-containing sustained-release composition capable of stabilizing a physiologically active protein or peptide, typically G-CSF by precipitation and retaining drug efficacy for several days in a living body owing to its sustained releasability is provided. Concretely, a zinc-containing sustained-release composition produced by forming...

20060210631 - Multi-particulate, modified-release composition: A multi-particulate, modified-release pharmaceutical composition for the oral administration of an active ingredient to the colon, wherein said particles comprise: (a) a core comprising an active ingredient or a pharmaceutically acceptable salt or ester thereof, and optionally one or more excipients; (b) a first coating applied to the surface of...

20060210632 - Sublingual coated tablet of fentanyl: The present invention relates to a fentanyl coated tablet and to the method for the preparation thereof....

20060210633 - Programmed drug delivery system: The present invention provides a programmed drug delivery system comprising: (a) a core composition comprising one or more beneficial agents and pharmaceutically acceptable excipients, wherein at least one excipient swells when exposed to an aqueous environment, (b) a coat surrounding the core composition, wherein the coat is impermeable to the...

20060210634 - Ceramic structures for controlled release of biologically active substances: The present invention provides compositions for controlled drug delivery, dosage forms, and processes for producing dosage forms. In a composition aspect of the present invention, a composition including a drug and a ceramic structure is provided. The ceramic structure has either a hollow portion wherein the drug is included in...

20060210635 - Injectable gel-forming compositions based on cross-linked and non-cross-linked polymers and the use thereof: The invention relates to injectable gel-forming compositions which contain an association of linear and cross-linked polymers and are embodied in the form of a suspension. The use of said compositions, in particular for filling pipes and cavities is also disclosed....

20060210638 - Injectable compositions of nanoparticulate immunosuppressive compounds: The invention is directed to an injectable nanoparticulate immunosuppressant composition for the formation of a subcutaneous or intramuscular depot. The invention is also directed to an injectable composition of nanoparticulate tacrolimus and/or sirolimus which eliminates the need to use polyoxyl 60 hydrogenated castor oil (HCO-60) and/or polysorbate 80 as a...

20060210639 - Nanoparticulate bisphosphonate compositions: Nanoparticulate bisphosphonate compositions, having an effective average particle size of less than 2000 nm, are described. The compositions are useful in treating bone resorption in a mammal....

20060210636 - Nanoscale core/shell particles and the production thereof: In methods for the production of nanoscale particles having a so-called core and at least one so-called shell, either nanoscale particles of an inorganic material having a particle size of <100 nm or nanoscale particles of a magnetic material having a particle size of <100 nm are used as the...

20060210640 - Process for producing nanoparticles by spray drying: Nanoparticles of a compound are produced by spraying a solution of the compound into a heated chamber. The resulting product comprises a free flowing mixture of nanoparticles of the compound....

20060210637 - Stable tablet dosage forms of proton pump inhibitors: This invention relates to a method of making oral formulations of practically water insoluble, or very slightly water soluble proton pump inhibitors, the oral dosage forms so made, and methods of use thereof. The oral dosage form has a core tablet of compressed particles composed of powder particles of a...

20060210641 - Absorbable microparticles: This invention pertains to a sustained release complex of one or more peptides, one or more proteins or a combination thereof immobilized on an absorbable polymer microparticle optionally having an absorbable polymer coating. The microparticle complex of this invention comprises a peptide(s) and/or protein(s) which have at least one amino...

20060210642 - Cardiac development promoting activity of perivitelline fluid of embryos of indian horseshoe crab, tachypleus gigas (muller): The present invention relates to a method for cardiac development activity in a subject comprising administering to the subject an appropriate amount of perivitelline fluid obtained from fertilized eggs of horseshoe crab....

20060210643 - Cartilage repair mixture containing allograft chondrocytes: The invention is directed toward a sterile cartilage defect implant material comprising milled lyophilized allograft cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran...

20060210644 - Materials, methods, and devices for treatment of arthropathies and spondylopathies: Novel modalities are introduced to treat joint and cartilage ischemia and related pathologies to improve outcome in the treatment of arthropathies and spondylopathies. The invention includes compositions, materials or devices which will improve oxygen, substrate and nutrient delivery to joint tissues and modalities to decrease the degradation of joint tissues...

20060210645 - Pharmaceutically acceptable carrier for ophthalmic compositions: A pharmaceutically acceptable carrier for ophthalmic compositions useful in treating or alleviating the symptoms of dry eye syndrome, elevated intra-ocular pressure, age-related maculopathy or age-related macular degeneration....

20060210646 - Accelerator for mineral absorption and use thereof: The present invention has an object to provide an accelerator for mineral absorption and a composition containing the accelerator. The object is solved by providing an accelerator for mineral absorption comprising cyclic tetrasaccharide and/or saccharide derivatives thereof and a composition containing the accelerator....

20060210647 - Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto: The present invention relates to the discovery that non-traditional export of certain pro-inflammatory cytokines lacking a signal sequence from a cell can be inhibited by copper chelation and/or administration to the cell of a truncated form of S100A13 lacking the basic residue portion. Further, copper chelation inhibits, inter alia, neointima...

20060210648 - Method for treating an inflammation or lesion caused by a virus: A method for treating an inflammation or lesion caused by herpesvirus, comprising topically applying to said inflammation or lesion a composition consisting essentially of a C1 to C3 monohydroxy alcohol or a C2 to C4 diol and a sufficient amount of an acid to adjust the pH of the composition...

20060210649 - Method and kit to cure chronic cough: The current invention is a method and kit to cure chronic cough, which is typically a dry cough. Chronic coughing is frequently caused by gastric acid which has been aerosolized by coughing, thereby causing hypersensitivity of the upper airway, leading to more coughing. This vicious cycle can torture the patient...

20060210650 - Supplemental dietary composition for promoting weight loss: Compositions, and methods for administering the same to humans, are provided for the promotion of healthy fast weight loss while providing an excellent source of calcium and containing antioxidants. The compositions preferably comprise three sources of calcium and include at least one of Calcium Carbonate, Vitamin D, caffeine-free Green Tea,...

20060210651 - Methods and compositions involving aldose reductase: Embodiments of the invention include methods and compositions for the inhibition of Aldose Reductase by nitric oxide. Certain embodiments of the invention include the induction of nitric oxide by administration of a nitric oxide donor, nitric oxide precursor, inhibitor of a nitric oxide synthase inhibitor, and/or an activator of nitric...

20060210652 - Extract of petasites japonicus having neuroprotective effect and antioxidant activity: The present invention relates to an extract of Petasites japonicus having antioxidant activity, and more particularly, to an extract of Petasites japonicus having antioxidant activity which is extracted using an alcohol and an antioxidant for the prevention and treatment of a brain disease comprising the extract as an effective ingredient....

20060210653 - Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition: Compositions and methods for administering the same to humans are provided for the promotion of increasing a person's natural metabolic rate, increasing thermogenesis, increasing training intensity, increasing muscular definition, and/or decreasing water retention. Said compositions comprise, green tea extract, anhydrous caffeine, theobroma cocao extract, oolong tea extract, white tea extract,...

20060210654 - Process for extracting vital components from plants: The present invention presents a cost effective process for separating between liquids extracted from whole plants or plant parts and the solid plant residue, and performing concurrent sterilization of both substances. This novel method comprising fast deep-freezing said whole plant(s) or parts thereof; crushing the deep-frozen whole plant(s), or parts...

20060210655 - Bioactive compositions, natural methods of producing them and computational methods for designing natural production processes: The present invention is directed to procedures for the controlled natural bioprocessing of naturally occurring biological molecules by processing activities present in select organisms, extracts of such organisms or other natural processing agents. The invention also covers the methods for developing these procedures and compositions prepared by the procedures....

20060210656 - Synergistic effects of nuclear transcription factor nf-kb inhibitors and anti-neoplastic agents: The present invention provides methods of inhibiting metastasis of a tumor and methods of treating a tumor using a combination of an inhibitor of the activation of nuclear factor NF-κB and a cancer chemotherapeutic agent. In one embodiment of the present invention, combination of curcumin and paclitaxel (taxol) can be...

20060210657 - Compositions and methods for prostate and kidney health and disorders, an herbal preparation: A composition including an aliquot of the herb Herba Epimedii; and an aliquot of at least three supplemental herbs selected from the group consisting of Fructus Rosae Laevigatae; Fructus Rubi; Fructus Psoralea; Radix Morindae Officinalis; Fructus Schisandrac Chinensis; Fructus Ligustri Lucidi; Semen Cuscutae; and Radix Astragali. A composition including icariin;...

20060210658 - Processes for obtaining (-)-guaiol and the use thereof: A process for obtaining oils of sesquiterpenes and sesquilactones and (−)-guaiol from the oil of Callitris intratropica, processes for encapsulation of the oil from Callitris intratropica, and the various uses of the oil and the encapsulated oil are described. The oils are suitable for various purposes in the personal care...

20060210659 - Anti-obesity agent: The object of the present invention is to provide an active substance which has an anti-obesity effect such as a triglyceride lowering activity, a cholesterol lowering activity and the like. The present invention provides a blood triglyceride lowering agent, a cholesterol lowering agent, a body fat storage suppressive agent, an...

20060210660 - Process for preparing an extract from ivy leaves: The present invention relates to a process for preparing an extract from ivy leaves which includes the active ingredient hederacoside C and α-hederin, and to extracts prepared by this process. According to this there is initially provision of a first, α-hederin-rich extract and subsequently provision of a second, hederacoside C-rich...

20060204435 - Detection, imaging, and depletion of intracellular pathogens: Methods and compositions are disclosed for detecting and depleting cells infected with bacteria of the Chlamydiaceae family from a biological sample. Compositions include, for example, an immunoglobulin constant region polypeptide linked to an imaging moiety or a bactericide. Methods include, for example, contacting a biological sample that includes chlamydia infected...

20060204436 - Tritiated growth hormone secretagogue mk-0677: The present invention relates to a tritiated growth hormone secretagogue which can be used for the identification of compounds capable of binding to growth hormone secretagogue receptors, or of compounds having activity as growth hormone secretagogues....

20060204437 - Chlorin and bacteriochlorin-based difunctional aminophenyl dtpa and n2s2 conjugates for mr contrast media and radiopharmaceuticals: where R1, R2, R2a R3, R3a R4, R5, R5a R6, R7, R7a, and R8 cumulatively contain at least two functional groups that will complex or combine with an MR imaging enhancing element or ion. The compound is intended to include such complexes and combinations and includes the use of such...

20060204439 - Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol: The invention relates to techniques for measuring and comparing relative molecular flux rates of different biological molecules by administering isotope-labeled water to one or more tissues or individuals and comparing the molecular flux rates of two or more biological molecules, including biological molecules in different chemical classes. The methods find...

20060204438 - Water soluble iron oxide nanoparticles and a method of its preparation: This invention relates to water soluble iron oxide nanoparticles and a method of its preparation. More specifically, this invention relates to a method of manufacturing water soluble iron oxide nanoparticles uniform in size by coating polyvinylpyrolidone, a biocompatible polymer that can be intravenously administered via thermal decomposition, on the surface...

20060204442 - Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents: The invention relates to magnetically targetable particles comprising at least one magnetic component The particles are capable of delivering selectively to a site or organ a biologically active substance for in vivo medical diagnosis and/or treatment. The particles are prepared by many processes such as encapsulation processes. Also described are...

20060204443 - Methods for tumor treatment using dendrimer conjugates: Methods are disclosed for treating a tumor. A dendrimer conjugate is administered to a subject having a tumor. The dendrimer of the dendrimer conjugate is a generation 5 DAB, generation 2 polylysine, or generation 6-8 PAMAM dendrimer. The dendrimer conjugate comprises an effective amount of an anti-tumor agent. The anti-tumor...

20060204444 - Protein cages for the delivery of medical imaging and therapeutic agents: The present invention is directed to novel compositions and methods utilizing delivery agents comprising protein cages, medical imaging agents and therapeutic agents....

20060204445 - Cell scaffold matrices with image contrast agents: The invention is directed to methods and compositions for monitoring remodeling of an artificial tissue construct using image or contrast enhancing agents. The invention allows the growth, development, and remodeling of the artificial tissue to be monitored....

20060204440 - Radio-opaque polymeric biomaterials: Iodinated and/or brominated derivatives of aromatic dihydroxy monomers are prepared and polymerized to form radio-opaque polymers. The monomers may also be copolymerized with other dihydroxy monomers. The iodinated and brominated aromatic dihydroxy monomers can be employed as radio-opacifying, biocompatible non-toxic additives for other polymeric biomaterials. Radio-opaque medical implants and drug...

20060204441 - Cell scaffold matrices with incorporated therapeutic agents: The invention is directed to methods and compositions for preparing matrices for controlled delivery of at least one therapeutic or biological agent to a target site in a subject. This is accomplished using nanoparticles coupled to the therapeutic or biological agent that are incorporated within the matrix or reacted on...

20060204447 - Small particle liposome aerosols for delivery of anticancer drugs: Provided herein is a method of treating primary lung cancer or metastatic cancer to the lung in an individual by delivering at least once to the respiratory tract of the individual via inhalation a nebulized liposomal aerosol comprising a dilauroylphosphatidylcholine liposome containing camptothecin or a derivative thereof in an amount...

20060204446 - Topical immunotherapy and compositions for use therein: The present invention is concerned with the use of at least one immunosuppressant, or a pharmaceutically acceptable salt, solvate of physiologically functional derivative thereof, in the treatment of topical immune disorders of the scalp, and scalp conditions, and compositions suitable for such use....

20060204449 - Nasal pharmaceutical composition of piribedil: The present invention relates to a pharmaceutical composition for the administration, by the nasal route, of piribedil in solution or in powder form....

20060204450 - Pharmaceutical compositions based on anticholinergics and pde 5-inhibitors: The present invention relates to novel pharmaceutical compositions based on anticholinergics and PDE 5-inhibitors, processes for preparing them and their use in the treatment of pulmonary hypertension....

20060204448 - Powdery preparation for nasal administration: According to the present invention, a powdery preparation for nasal administration comprising a physiologically active substance, a non-water-absorbing and hardly water-soluble powder(s) and one or two selected from the group consisting of a mucolytic agent and a nonionic surfactant is provided....

20060204451 - Chewing gum in the form of multi-layer tablets: Disclosed are tablets having a sandwich-like structure comprising at least one inner layer of gum base containing one or more active pharmaceutical, dietetic or nutritional ingredients and two non-contigous outer layers comprising antiadhesion excipients and compression adjuvants preventing the adhesion to the punches of the tabletting machine and possibly active...

20060204452 - Antimicrobial film-forming dental compositions and methods: The present application provides dental compositions, methods of making, and methods of using dental compositions that include an antimicrobial lipid component and a water-dispersible, polymeric film-former....

20060204453 - Oral care cleaning compositions and methods: An oral cleaning composition including an orally-acceptable cleaning solvent, an orally-acceptable surfactant and an orally-acceptable alkaline agent. Some implementations include one or both of charged and neutral surfactants. In many instances, the cleaning solvent is ethanol, the surfactant is sodium laurel sulfate and the alkaline agent is potassium hydroxide. An...

20060204454 - Method for improving the functional properties of a globular protein, protein thus prepared, use thereof and products containing the protein: The invention relates to a method for improving the functional properties of globular proteins, comprising the steps of providing a solution of one or more globular proteins, in which solution the protein(s) is/are at least partially aggregated in fibrils; and performing one or more of the following steps in random...

20060204455 - Compositions for enhancing effects of other oral care compositions: An enhancing composition comprising a solvent and a base compound creates an alkaline environment for activating peroxide whiteners and accelerating the formation of free radicals from the peroxide to effect the oxidation of organic molecules causing staining of the dentition. In one embodiment, potassium hydroxide is dissolved in water to...

20060204458 - Anti-aging methods and composition: An anti-aging method and composition are disclosed. The composition is a micro-cluster water having anti-oxidant and free-radical quenching properties. The method involves contacting a cell or portion thereof in danger of free-radical or oxidant damage with the micro-water....

20060204457 - Cosmetic uv-screen compositions and aminobutadiene-based uv-absorbing complexes therefor: This invention relates to a cosmetic composition for protection against UV radiation and its detrimental effects comprising a cosmetically and dermatologically acceptable carrier and a UV absorbing compound, not being flavonoid, which is covalently linked to a carrier molecule....

20060204456 - Titanium oxide particles having useful properties and method for production thereof: Titanium dioxide particles having a selective shielding effect against infrared radiation and a high spreadability are disclosed. The titanium dioxide particles have a primary particle size of 0.5 to 2.0 μm and a visible light transmission of less than 95%. The titanium oxide particles consist essentially of 0.05 to 0.4%...

20060204459 - Use of tyrosine inhibitors for whitening human skin and treating melanocyted dysfunction associated diseases: The present invention relates to a method for whitening human skin and treating melanocyte dysfunction associated diseases comprising administering a tyrosine kinase inhibitor to a human in need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably, said inhibitor is unable to promote death of IL-3...

20060204461 - Ester-terminated poly(ester-amide) in personal care products: A resin composition is prepared by reacting components comprising dibasic acid, diamine, polyol and monoalcohol, wherein (a) at least 50 equivalent percent of the dibasic acid comprises polymerized fatty acid; (b) at least 50 equivalent percent of the diamine comprises ethylene diamine; (c) 10-60 equivalent percent of the total of...

20060204460 - Lip gloss composition: The present invention provides a lip gloss composition having appropriate adhesion, spreadability, durability, practical properties such as gloss on the applied surface, storage stability, and safety to skin. A lip gloss composition, comprising (A) 20 to 60 parts by mass of polyglyceryl-2 dimer dilinoleate isostearate and/or hydrogenated polyisobutene; (B) 0.5...

20060204462 - Michael addition product and schiff's base aromachemicals: wherein R1 is H, an aliphatic group or an aromatic group, R2 is an aliphatic group or an aromatic group, provided that the total number of carbon atoms in the groups R1 and R2 is 10 or more; Z is CH2 or O, n is 0 or 1, such that...

20060204463 - Enhanced efficacy aluminum or aluminum-zirconium antiperspirant salt compositions containing calcium salt(s) and betaine: An antiperspirant composition comprising an antiperspirant salt selected from an aluminum antiperspirant salt, an aluminum-zirconium antiperspirant salt, and a mixture thereof; a betaine component selected from betaine, betaine hydrochloride, and a mixture thereof; a calcium salt; and water....

20060204464 - Macrocyclic thiiranes: wherein Z is CH2, CH═CH or CHSCH (thiirane), provided that if two or more Z are CH═CH they are not conjugated and wherein n is selected so that the total number of carbon atoms is from 8 to 20. Mixtures of these compounds, methods for their preparation, their use as...

20060204470 - Care and /or make-up cosmetic composition structured with silicone polymers: Care and/or make-up cosmetic composition comprising: a liquid continuous fatty Phase structured with at least one structuring polymer (homopolymer or copolymer) having a weight-average molecular mass ranging from 500 to 500 000, containing at least one moiety comprising: at least one polyorganosiloxane group consisting of I to 1 000 organosiloxane...

20060204468 - Cosmetic emulsions with long-term stability: Low-viscosity, finely divided oil-in-water emulsions with long-term stability, comprising an emulsifier combination of noncarbohydrate polyol partial esters of linear or branched, saturated or unsaturated fatty acids having 6 to 22 carbon atoms (emulsifier component A) and emulsifiers based on carbohydrate (emulsifier component B), one or more oils, and preservative are...

20060204466 - Hydroalcoholic antimicrobial composition with skin health benefits: The invention pertains to an alcohol based antimicrobial skincare composition. The invention also pertains to an alcohol based antimicrobial skincare composition with skin health benefits including moisturization and skin barrier maintenance effects. The invention further pertains to an alcohol based antimicrobial skincare composition that is a stable emulsion that has...

20060204467 - Hydroalcoholic antimicrobial composition with skin health benefits: The invention pertains to an alcohol based antimicrobial skincare composition. The invention also pertains to an alcohol based antimicrobial skincare composition with skin health benefits including moisturization and skin barrier maintenance effects. The invention further pertains to an alcohol based antimicrobial skincare composition that is a stable emulsion that has...

20060204469 - Stable mixed emulsions: Stable mixed emulsion systems containing at least two discrete and distinctly different dispersed particle size ranges, i.e., both nanoemulsion and macroemulsion semisolid dispersions, as well as a method of making the same, are disclosed. The stable mixed emulsions may be used for cosmetic and dermatological applications and provide unique benefits....

20060204465 - Methods of preparing powdered cosmetic or pharmaceutical compositions containing methyl methacrylate polymers as a texturing agent: Use of a polymer or of a blend of polymers chosen from copolymers or terpolymers of methyl methacrylate with one or more monomers chosen from acrylic acid esters or methacrylic acid esters, as a texturing agent in cosmetic or pharmaceutical compositions formulated in the form of powders that may be...

20060204471 - Compositions and regime/regimen for treating the adverse signs of cutaneous skin aging: Cosmetic/dermatological compositions suited for combating the adverse signs of cutaneous skin aging, notably for maintaining and/or enhancing the thickness of the skin, particularly the thickness of the epidermis, comprise a thus-effective amount of at least one substance/species which is active with respect to the trophicity of the cutaneous nerves and/or...

20060204472 - Multifunctional dendrimers and hyperbranched polymers as drug and gene delivery systems: The present invention deals with the synthesis of multifunctional dendrimeric and hyperbranched polymers for application as drug delivery systems of bioactive pharmaceutical compounds and as gene delivery systems (carriers of genetic material), the latter through condensation with genetic material. Specifically, the present invention deals with the synthesis of multifunctional compounds...

20060204473 - Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same: The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide...

20060204474 - Treatment of epithelial layer lesions: Methods for the treatment of lesions originating in an epithelial layer, particularly diseases of the epithelium of the skin, bladder, oral mucosa, vagina and cervix are described. Also described are uses and formulations for the treatment of lesions originating in an epithelial layer....

20060204479 - Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same: The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors....

20060204477 - Helper virus-free herpesvirus amplicon particles and uses thereof: The invention features new helper virus-free methods for making herpesvirus amplicon particles that can be used in immunotherapies, including those for treating any number of infectious diseases and cancers (including chronic lymphocytic leukemia, other cancers in which blood cells become malignant, lymphomas (e.g. Hodgkin's lymphoma or non-Hodgkin's type lymphomas). Described...

20060204475 - Melan-a peptide analogue-virus-like-particle conjugates: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP which can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs), and particular peptides derived from MelanA...

20060204478 - Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis: Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed....

20060204480 - Replication competent virus or its recombinant for use in cancer therapy: A method for treatment of a central nervous system cancer in an individual which includes administration, preferably peripheral administration, of a replication competent alphavirus of the Semliki Forest family, or its recombinant, to the individual....

20060204476 - Treating hepatocellular carcinomas using therapeutic viruses: An interferon-sensitive, replication-competent RNA virus is used to treat a mammalian subject having a hepatocellular carcinoma tumor....

20060204485 - Probiotics in the treatment of atypical depression and other disorders characterised by hypothalamic pitiuitary-ardrenal axis over activity: A method of treating a disorder characterized by hypothalamic-pituitary-adrenal axis over-activity comprising administering to a subject a probiotic bacterium....

20060204484 - Storage stable frozen lactic acid bacteria culture: A storage stable frozen lactic acid bacteria (LAB) culture that comprises LAB that are that are able to utilize sucrose, has a weight of at least 50 g frozen material and a content of viable bacteria of at least 109 colony forming units (CFU) per g frozen material....

20060204483 - Cellular telomerase vaccine and its use for treating cancer: The invention provides dendritic cell (DC) preparations that present a telomerase reverse transcriptase (TRT) peptide in the context of an MHC class I or MHC class II molecule. The DCs may be pulsed with a TRT polypeptide, or may comprise a recombinant polynucleotide encoding TRT. The invention also describes the...

20060204482 - Methods of islet isolation and transplantation: The present invention relates to methods for improving the viability and recovery of islets that are separated from a donor organ for subsequent transplantation. In a preferred embodiment, the islets are separated from a donor pancreas and transplanted into the liver of a diabetic patient. One or more emulsified perfluorocarbons...

20060204481 - Methods of promoting cell viability: Methods for promoting viability of a transplant cell population by administering a hydrophilic bile acid, such as ursodeoxycholic acid (UDCA), salts thereof, and analogs thereof (e.g., glycoursodeoxycholic acid and tauroursodeoxycholic acid)....

20060204486 - Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases: The invention relates to new pharmaceutical compositions for the treatment and/or prevention of schizophrenia and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment...

20060204487 - Production of high mannose proteins in plant culture: A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes...

20060204488 - Methods for treating adhesive capsulitis: The invention relates to the discovery that collagenase injections are effective in lyse the collagenous adhesions in the shoulder and treat the disorder, adhesive capsulitis. As such, the invention relates to methods of treating or preventing adhesive capsulitis, or frozen shoulder, in a patient in need of such treatment comprising...

20060204489 - Protein c derivatives: Novel human protein C derivatives are described. These derivatives have increased anti-coagulation activity compared to wild-type protein C and retain the biological activity of the wild-type human protein C. These derivatives will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of acute...

20060204490 - Hemostatic compositions containing sterile thrombin: The present invention includes sterilized hemostatic compositions that contain a continuous, biocompatible liquid phase having a solid phase of particles of a biocompatible polymer suitable for use in hemostasis and that is substantially insoluble in the liquid phase, and sterile thrombin, each of which is substantially homogenously dispersed throughout the...

20060204491 - Titanium oxide-organic polymer conjuction suitable for artificial bone: The titanium oxide-organic polymer composite material for artificial bone obtained by forming titania gel on the surface of said base material by titania solution treatment to dip into a solution of 0° C. to 50° C. temperature for from several seconds to 1 week obtained by adding a solution consisting...

20060204492 - Compositions and methods for producing enhanced antibodies: The invention provides a Vitaxin antibody and a LM609 grafted antibody exhibiting selective binding affinity to αcβ3. The Vitaxin antibody consists of at least one Vitaxin heavy chain polypeptide and at least one Vitaxin light chain polypeptide or functional fragments thereof. Also provided are the Vitaxin heavy and light chain...

20060204493 - Heteromultimeric molecules: The invention provides heteromultimeric antibodies, and methods of making these antibodies at high yields and purity. The invention also provides methods and compositions for using these antibodies....

20060204494 - Methionine sulfoxide antibodies: Antibodies specific for methionine sulfoxide residues on proteins are provided. The antibodies are prepared using methionine-rich zein proteins, which are oxidized, as antigens....

20060204495 - Isolation and identification of cross-reactive t cells: Cross-reactive T cells recognizing both MBP93-105 and HHV-61-13 peptides represent a significant subset of T cells with some degree of TCR degeneracy. It appears that the recognition of the cross-reactive T cells has a less stringent requirement for the flanking residues of the two peptides. In contrast, these flanking residues...

20060204496 - Agonist antibody against heteroreceptor: Animals were immunized with either the A or B chain of a receptor, and then mRNA was extracted from the spleen cells of the animals, and the variable regions of the L and H chains were isolated by RT-PCR using primers for variable regions comprising CDRs. Single-chain Fv was synthesized...

20060204497 - Cytotoxicity mediation of cells evidencing surface expression of cd63: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The...

20060204498 - Novel antagonists of cxcr3-binding cxc chemokines: Novel antagonists of CXCR3-binding CXC chemokines, and in particular of human CXCL11, can be obtained by generating mutants of such chemokines in which the binding to glycosaminoglycans (GAGs) is impaired due to non-conservative substitutions of amino acids involved in this interaction. Compounds prepared in accordance with the present invention can...

20060204499 - Tumour necrosis factor binding ligands: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of...

20060204500 - Methods for modulating expression of an hiv-1 fusion cofactor: The invention relates to a method for modulating HIV-1 fusion cofactor expression by manipulating CTLA-4 on the surface of T cells. The invention encompasses methods for modulating HIV-1 fusion cofactor expression by inhibiting one or more intracellular signals resulting from stimulation of CTLA-4. In one embodiment, expression of the HIV-1...

20060204506 - Anti-mesothelin antibodies: This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well...

20060204501 - Drug for cancer therapy: A lactoferrin hydrolysate mixture or lactoferrin partial peptide that can be obtained by hydrolyzing lactoferrin with a hydrolytic enzyme and has an action of enhancing cytotoxic activity of an antibody drug in an antibody therapy of cancer is used as an active ingredient of a drug for enhancing cytotoxic activity...

20060204502 - Enhancing treatment of cancer and hif-1 mediated disorders with adenosine a3 receptor antagonists: The present invention relates to the use of adenosine receptor antagonists, preferably A3 receptor antagonists, either alone or in combination with other agents for the treatment, prevention and/or management of diseases or disorders associated with overexpression of HIF-1α and/or increased HIF-1α activity (e.g., cancer, respiratory disease). The methods and compositions...

20060204504 - Methods and compositions for treating conditions of the eye: Provided are methods and compositions for treating ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of, for example, a photodynamic therapy (PDT)-based approach can be enhanced by combining the PDT with an anti-FasL factor, for example, an anti-FasL...

20060204505 - Methods for identifying tumors responsive to treatment with her dimerization inhibitors (hdis): Tumors are identified as responsive to treatment with HER dimerization inhibitors (HDIs) are identified by treating a HER expressing tumor with an HDI (which may be the same or different from that contemplated for treatment), and determining the reactivity of the tumor with the HDI. Lack of or diminished reactivity...

20060204503 - Treatment of cancer using antibodies to polypeptides differentially expressed in human lung tumors: The present invention is directed to novel methods of treating, indentifying or diagnosing a hyperproliferative disorder in a patient in need thereof. The methods of the invention include administering to a patient a composition comprising a binding molecule which binds to a cell surface expressed glycoprotein expressed predominantly in tumor...

20060204509 - Accelerated cd8+ t-cell memory after dendritic cell vaccination: Disclosed are compositions and methods for Here, it is shown that vaccination with peptide-coated dendritic cells (DC) generated antigen-(Ag)-specific CD8+ T-cells with the phenotype and function of memory T-cells as early as 4-6 days after immunization. These memory-like CD8+ T-cells underwent vigorous secondary expansion, resulting in rapid generation of elevated...

20060204510 - Bv8 nucleic acids and polypeptides with mitogenic activity: The present invention provides methods of using Bv8 polypeptides to induce endothelial cell proliferation and to enhance endothelial cell survival. Also provided herein are methods of screening for modulators of Bv8 activity. Furthermore, methods of treatment using Bv8 polypeptides are provided....

20060204507 - Method for generating an immune response and reagents therefor: Isolated peptides are disclosed which, when processed, generate a coordinated immune response....

20060204508 - Treatment of autoimmune diseases using an activator for the notch signalling pathway: A product is disclosed comprising i) a modulator of the Notch signalling pathway; and ii) an autoantigen or bystander antigen, or a polynucleotide coding for an autoantigen or bystander antigen; as a combined preparation for simultaneous, contemporaneous, separate or sequential use for modulation of immune response....

20060204512 - Polypeptide compounds for inhibiting angiogenesis and tumor growth: In certain embodiments, this present invention provides polypeptide compositions, including compositions containing a modified polypeptide, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases....

20060204511 - Use of recombinant or synthetic gelatin as stabiliser in vaccines: The invention relates to methods for preparing vaccine and pharmaceutical compositions comprising recombinant or synthetic gelatin as a stabiliser and to the vaccine and pharmaceutical formulations themselves, as prepared by these methods....

20060204513 - Novel surface protein (hbsag) variant of the hepatitis b virus: The invention relates to sequences of a novel variant of the Hepatitis B surface antigen (HBsAg) and to methods for detecting, in patient samples, nucleic acids, antigens and antibodies directed against the same....

20060204515 - Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi: Unique compounds that can be used for inducing an immune response to Borrelia burgdorferi in a subject by administering a therapeutically effective amount of the glycolipid to the subject. Such administration is particularly useful for preventing or treating Lyme disease in a subject. The compounds(s), and therapeutically acceptable salts thereof,...

20060204514 - Expression of hydrophobic proteins: Methods are disclosed for the design of non-native (i.e. heterologous) polypeptides comprising a proportion of hydrophobic amino acids which have an increased probability of being efficiently expressed in an expression system such as a bacterial host (e.g. E. coli). The methods involve identifying one or more hydrophobic peptide sequences within...

20060204516 - Compositions and methods for enhancing the immunogenicity of antigens: The present invention includes compositions, methods and kits for enhancing the immunogenicity of an antigen via fusion to a Listerial protein. The present invention further encompasses Listeria vaccine strains for enhancing the immunogenicity of an antigen....

20060204517 - Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols: A composition for treating insulin-dependent diabetes, reducing body fat, improving insulin sensitivity, reducing hyperglycemia, and reducing hypercholesterolemia with at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol is disclosed. A method of treating a subject suffering from insulin-dependent diabetes by administering a composition that includes...

20060204518 - Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols: A composition for treating insulin-dependent diabetes, reducing body fat, improving insulin sensitivity, reducing hyperglycemia, and reducing hypercholesterolemia with at least one chromium complex and a conjugated fatty acid or conjugated fatty alcohol is disclosed. A method of treating a subject suffering from insulin-dependent diabetes by administering a composition that includes...

20060204519 - Adeno-associated virus materials and methods: The present invention provides adeno-associated virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV....

20060204520 - Vaccine composition: The present invention relates to the field of novel, engineered Gram-negative bacterial strains that have improved outer-membrane vesicle shedding properties, and vaccine compositions comprising these bacteria or vesicles. The present invention provides a hyperblebbing Gram-negative bacterium which has been genetically modified by either or both processes selected from a group...

20060204521 - Vector carrying a polynucleotide which encodes a polypeptide having the ability to stimulate an immune response against the polypeptide of seq id no:24: The invention provides a nucleotide sequence representing a pathogenicity island found in species of pathogenic mycobacteria. The islands are shown as SEQ ID NOS: 3 and 4 and comprises several open reading frames encoding polypeptides. These polypeptides and their use in diagnosis and therapy form a further aspect of the...

20060204522 - Immunogenic compositions comprising lawsonia intracellularis: The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the...

20060204523 - Flavivirus vaccine delivery system: A flaviviral expression vector, construct and system are provided that each comprise a flaviviral replicon that faciliates intracellular self-replication leading to high-level expression of RNA and protein(s) encoded by a heterologous nucleic acid. The flaviviral expression vector, construct and system preferably use a Kunjin virus replicon and are of particular...

20060204524 - Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof: The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a...

20060204525 - Compositions and methods for preventing and treating anthrax diseases: Compounds, methods for identifying compounds and methods for using compounds which modulate interaction of lethal factor and anthrolysin O in the treatment and prevention of anthrax diseases are provided....

20060204526 - Emulsive composition containing dapsone: The present invention relates to a topical, emulsive composition containing Dapsone or its derivative. The inventive composition incorporates emollients and Dapsone or its derivative in a stable emulsion. The stability is achieved through the use of a combination of certain surfactant mixtures and an enhancer providing solubility of the Dapsone....

20060204530 - Benzoyl peroxide compositions and methods of use: Solutions of benzoyl peroxide, in one or more solvents are provided that are suitable for direct topical application to the skin of a user or can be formulated into a product that is suitable for topical application to the skin of a user. In embodiments, the solutions include benzoyl peroxide...

20060204529 - Crosslinked elastin and process for producing the same: A crosslinked elastin, a water-soluble crosslinking agent to be used for crosslinking, molded elastin articles, medical instruments and regeneration tissues using the crosslinked elastin, and a surgical therapy method and regeneration treatment wherein the medical instruments are employed. There is provided a biocompatible functional material having elasticity suitable for transplantation...

20060204527 - Porous particles and cosmetics: The invention provides porous particles having a small particle diameter of 75 μm or less on the average, the porous particles further containing an active ingredient, a process for producing the porous particles, and cosmetics containing the porous particles. The invention relates to porous particles having an average particle diameter...

20060204528 - Surface-modified nanoparticles, their preparation and use: The invention relates to surface-modified nanoparticles composed of metal or semimetal oxides or hydroxides and having been reacted on their surface with a modifier, with formation of covalent bonds. The modifier is a polysiloxane. The invention also relates to a process for preparing the nanoparticles, to their use as fillers...

20060204531 - Robotic pest removal system: An autonomous robotic system and method for removing pests from a specific location. The robotic system of the invention preferably comprises a means for attracting pests to at least one specific location; and a robotic means for collecting and/or exterminating pests attracted to the specified location. In certain embodiments, the...

20060204536 - Biointerface membranes incorporating bioactive agents: A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen...

20060204535 - Cell-friendly cannula and needle: An improved cannula and method for making the same are disclosed. The cannula includes a lumen having a polished inner surface, and a first hydrophilic coating on the polished inner surface of the lumen. The cannula can also include a polished outer surface, and a second hydrophilic coating on the...

20060204533 - Drug delivery compositions and related methods: A drug delivery composition includes a polymer, and one or more drugs and a bioactive polyelectrolyte complex dispersed within the polymer where the polyelectrolyte complex regulate the release of the drugs from the polymer. The bioactive polyelectrolyte complex comprises a polyelectrolyte and an oppositely charged component, wherein the polyelectrolyte and/or...

20060204534 - Drug delivery system and method of manufacturing thereof: Medical devices implanted or otherwise used in a mammal are made less prone to trigger adverse reactions by use of gas cluster ion-beam (GCIB) surface modification adhere various drug molecules directly into or onto the surface of medical devices, and optionally building adhered drug layers upon the first adhered layer...

20060204532 - Drug delivery systems and methods for modulating the fetal environment and pregnancy process: Systems and Methods are described for treatment of fetal disorders, promotion of fetal health, and extension of the pregnancy period. A drug delivery system (DDS) can perform both bolus and continuous delivery of substances in accordance with sensed data reflecting the current state of a fetus. The methods and systems...

20060204544 - Allograft bone composition having a gelatin binder: The invention is directed toward an osteoimplant for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth inducing composition of demineralized allograft bone material mixed with an aqueous phosphate buffered gelatin which when lyophilized to remove water from the...

20060204541 - Coatings, coated articles and methods of manufacture thereof: A multi-layer coating is particularly useful for the coating of implants such as orthopedic and dental implants, particularly metallic implants. The first layer comprises a dense material insoluble and inert in body fluids. The second layer comprises apatite and a binder. The first layer protects the metallic implants from corrosion,...

20060204542 - Coatings, coated articles and methods of manufacture thereof: A multi-layer coating is particularly useful for the coating of implants such as orthopedic and dental implants, particularly metallic implants. The multi-layer coating has both high bond strength to implants and excellent bioactivity with the surrounding body tissue. A method of making a coated implant includes depositing a first layer...

20060204540 - Controlled release formulations of octreotide: A formulation of octreotide or pharmaceutically acceptable salts thereof, which provides controlled release of a therapeutically effective amount of octreotide for a period of at least about two months. Methods of treating acromegaly, decreasing growth hormone, decreasing IGF-1, and treating conditions associated with carcinoid tumors and VIPomas by administering a...

20060204539 - Electrospun cell matrices: The invention is directed to compositions and methods for preparing electrospun matrices comprising at least one natural biological material component and at least one synthetic polymer material. The natural component makes the matrices highly biocompatible while the molecular weight polymer component can impart additional strength mechanical strength to the scaffold...

20060204543 - Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents: Combinations of hydrophilic and hydrophobic entities in a biodegradable sustained release implant are shown to modulate each other's rate of release. Formulations of a therapeutically active agent and modulator provide substantially constant rate of release for an extended period of time....

20060204538 - Metallic nanoparticles as orthopedic biomaterial: A composition for use as a prosthetic biomaterial and associated method. The biomaterial exhibits cytocompatibility, mechanical functionality and osteoblast adhesion between the implant and interfacing surface. The biomaterial is metallic, has a grain size less than about 500 nanometers and has a surface roughness of less than about 800 nm...

20060204537 - Silicone blends and composites for drug delivery: The present invention provides a composition for use in delivering a drug into the body of a mammal, wherein the composition comprises silicone elastomer, an adjuvant polymer, and the drug. This composition may be part of an implantable medical device, such as a stent or a vascular or other graft...

20060204545 - Drug release regions for medical devices, which include polycyclic-structure-containing polymers: According to an aspect of the present invention, implantable or insertable medical devices are provided, which contain polymeric release regions that control the release of one or more therapeutic agents. The polymeric release regions, in turn, contain one or more polymers that contain one or more rigid, nonplanar polycyclic molecular...

20060204547 - Drug delivery stent with extended in vivo release of anti-inflammatory: A method for decreasing the level of restenosis following a stent placement medical intervention involves the continuous administration of a dose of an anti-restenotic agent, such as Pimecrolimus, from the stent to vascular tissue in need of treatment in a controlled and extended drug release profile for a period of...

20060204546 - Methods and systems for delivering immunosuppressant and anti-inflammatory agents from a stent: A method for decreasing the level of restenosis following a stent placement medical intervention involves the continuous administration of a dose of an immunosuppressant or anti-inflammatory agent from reservoirs in a stent to vascular tissue in need of treatment in a controlled, two phase drug release profile. It is envisioned...

20060204548 - Microimplants for ocular administration: Implants and microimplants are provided comprising homogeneous mixtures of active ingredient and bioerodible polymer, including microimplants having diameters of 0.019 inches or less and which can be delivered to the eye using self-sealing methods. Methods of manufacturing the implants and microimplants are provided that yield batches of highly uniform implants...

20060204550 - Food and beverages containing l-carnitine derivatives: The present invention relates to foods and/or. beverages containing L-carnitine derivatives that can be used to supplement L-carnitine deficiencies and/or preserve one or more properties of the foods and/or beverages....

20060204549 - Method of improving nutrient utilisation by a mammal and a composition for use therein: The invention relates to a method of stimulating nutrient utilization, especially through improved gastric emptying, comprising oral administration of a nutritional composition. The invention is concerned with a method of improving nutrient utilization by a mammal comprising orally administering a lactoferrin-containing nutritional composition to the mammal in an amount effective...

20060204551 - Synergistic salivation agents: Provides is a salivation cocktail that comprises a food acid and a tingling sensate. The combination of a food acid and a tingling sensate has been found to synergistically increase salivation....

20060204554 - Compositions and methods providing rumen bypass protein in ruminant diets: The present invention is based on the discovery that moist heat treated ruminant animal feed compositions comprising a fermentation biomass, have increased amounts of proteinaceous matter that escapes fermentation within the rumen. The ruminant animal feed compositions may further comprise, alone or in combination, one or more of an isolated...

20060204553 - Feed composition: A feed supplement comprising at least one selected from lactic acid bacterium belonging to Lactobacillus gasseri, a crushed product of the lactic acid bacterium, culture of the lactic acid bacterium, residue of the culture of the lactic acid bacterium and a treated product thereof (a concentrate, a pasted product, a...

20060204552 - Skin composition: The present invention provides a composition preferably a pet foodstuff comprising pantothenic acid, nicotinamide, histidine, inositol and choline wherein pantothenic acid is provided at a level of 10 mg to 500 mg per 400 kcal per day, its use in the treatment of a skin disorder and methods of controlling...

20060204558 - Antimicrobial pet wipes and methods: The present application provides pet wipes with antimicrobial compositions, and methods of using the pet wipes....

20060204556 - Cell-loaded prostheses for regenerative intraluminal applications: Cell-loaded devices or prostheses having various applications such as insertion into body passages are disclosed. The prostheses include cell carrier portions which are compatible with living tissue and which are loaded with therapeutic cell populations, and the prostheses can be applied within or replace one or more of narrow segments,...

20060204559 - Fast dissolving orally consumable films containing an ion exchange resin as a taste masking agent: Physiologically acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer, such as pullulan, and a taste masked pharmaceutically active agent, such as dextromethorphan. The taste masking agent is preferably a sulfonated polymer ion exchange resin comprising polystyrene cross-linked with divinylbenzene, such as AMBERLITE. Methods...

20060204555 - Thermosensitive polymers for therapeutic use and methods of preparation: A process for preparing a thermosensitive polymer from a microemulsion is provided. The microemulsion comprises a monomer capable of forming a thermosensitive polymer and a polymerizable surfactant. Additional comonomers may be included in the microemulsion to vary the properties of the polymers produced. The resulting thermosensitive polymers may be nanoporous....

20060204557 - Water-based personal moisturizers and lubricants, in particular vaginal lubricants, and uses thereof: There is a need for water-based sperm- and egg-friendly vaginal lubricant. We describe novel water-based nature-friendly personal moisturizers and lubricants that relive vaginal dryness. In addition to being non-spermicidal, sperm- and egg-friendly and biological-fluids mimicking, these personal moisturizers and lubricants also enhance sperm survival and motility, promote binding of sperm...

20060204560 - Wound dressing consisting of a biodegradable biopolymer: A hydrophilic pliable wound dressing consisting of biopolymers creates a new approach to wound dressing by providing a self-assembling hydrophilic gel type moisture permeable barrier applicable to a wide range of wound sizes and depths. Biodegradability and water solubility enable rapid and safe disposal, obviating a significant problem that occurs...

20060204561 - Device for delivery of trpv1 agonists: Described here are drug delivery devices including an occlusive backing layer and a drug depot containing a TRPV1 agonist and a non-hydrophilic solvent. The drug depot may take various forms, such as an adhesive polymeric matrix, liquid reservoir, or microreservoir droplets. Methods of making and using the drug delivery devices...

20060204562 - Microprojection arrays with improved biocompatibility: A transdermal delivery member having a plurality of microprojections adapted to pierce the stratum corneum of a subject, each of the microprojection having a length less than 145 microns. In a preferred embodiment, each microprojection has a length in the range of approximately 50-145 microns....

20060204563 - Compositions and kits for the removal of irritating compounds from bodily surfaces: The invention provides compositions, methods and kits for the removal of harmful or irritating substances from bodily surfaces. Kits may include a composition containing capsaicin and a capsaicin-cleaning composition, e.g., a composition in which capsaicin is soluble....

20060204564 - Compositions and kits for the removal of irritating compounds from bodily surfaces: The invention provides compositions, methods and kits for the removal of harmful or irritating substances from bodily surfaces. Kits may include a composition containing capsaicin and a capsaicin-cleansing composition, e.g., a composition in which capsaicin is soluble....

20060204565 - Conjugates and use thereof: e

20060204566 - Novel liposome complexes for increased systemic delivery: Highly efficient cationic liposomes have been developed as an improved delivery system for biologically-active reagents. A novel structure, the sandwich liposome, is formed and comprises one or more biologically active agents internalized between two bilomellar liposomes. This structure protects the incoming agent and accounts for the high efficiency of in...

20060204567 - Potato proteinase inhibitor ii exhibits activity in elevating fasting plasma cholecystokinin concentrations: A method of increasing fasting levels of cholecystokinin in a subject by the administration of potato proteinase inhibitor II is described. A method for extending satiety in a subject with elevated fasting cholecystokinin levels due to treatment is also described, along with a method of identifying subjects likely to respond...

20060204569 - Functional starch powder: Functional starch powder of 400% or more water retention capacity, 5 hr or more collapse time and 200 g or more gel indentation load. This functional starch powder is produced through the step of heating a starch raw material in the presence of water at 60 to 150° C. so...

20060204568 - Oral pharmaceutical preparation for proton pump antagonists: The invention relates to novel dosage forms for proton pump antagonists....

20060204570 - Preparing method for controlled released type tablet tamsulosin hcl and the tablet thereof: The present invention relates to a simple and effective method for preparing a tamsulosin HCl sustained-release tablet and a tamsulosin HCl sustained-release tablet produced thereby. The method comprises the steps of: dissolving tamsulosin HCl as an active ingredient in an organic solvent; dissolving the tamsulosin HCl solution in hydroxypropylmethylcellulose phthalate...

20060204572 - Solid dispersions or solid dispersion pharmaceutical preparations of phenylalanine derivatives: The present invention provides solid dispersions or solid dispersion pharmaceutical preparations containing a water-soluble polymeric substance(s) and a phenylalanine compound of the formula (1) or pharmaceutically acceptable salts thereof, wherein A represents the formula (2) and the like, B represent an alkoxy group and the like, E represents a hydrogen...

20060204571 - Stable compositions of bupropion or its pharmaceutically acceptable salts: A stable oral pharmaceutical composition comprising a therapeutically effective amount of bupropion or its pharmaceutically acceptable salt intimately blending with one or more compatible excipients selected from the group consisting of talc and potassium chloride, additional pharmaceutically acceptable excipients and total impurities are present in amounts from 0% to not...

20060204573 - Control release formulation containing a hydrophobic material as the sustained release agent: The present invention is directed to a sustained release pharmaceutical composition in oral dosage form consisting essentially of a pharmaceutically effective amount of a medicament and a hydrophobic material in the absence of a lactose or hydrophobic carbohydrate polymer, said medicament being present in an amount greater than about 25%...

20060204574 - Sustained-release oral administration preparation of phenylalanine derivatives: The present invention provides sustained-release oral administration preparations containing the phenylalanine compound of the formula (1) wherein A represent the formula (2) and the like; B represents an alkoxy group and the like; E represents a hydrogen atom and the like; D represents a substituted phenyl group and the like;...

20060204575 - Amphetamine formulations: Amphetamine formulations comprise a plurality of particles comprising two or more pharmaceutically active amphetamine salts, wherein the dosage form, when administered under fed conditions provides a reduced variability in bioavailability as compared to the dosage form administered under fasted conditions....

20060204576 - Multilayer dosage forms, which contain active substances and which comprise a neutral core, and an inner and outer coating consisting of methacrylate copolymers and methacrylate monomers: The invention relates to a multilayer dosage form comprised of: a) a neutral core; b) an inner coating consisting of a methacrylate copolymer; c) an outer coating consisting of a copolymer of which 40 to 95% by weight is composed of radically polymerized C1 to C4 alkyl esters of acrylic...

20060204577 - Pharmaceutical compositions of drugs and neutralized acidic polymers: Pharmaceutical compositions comprised of low-solubility and/or acid-sensitive drugs and neutralized acidic polymers are disclosed....

20060204578 - Dual controlled release dosage form: A dosage form that provides a controlled release of at least two different active agents is provided. Particular embodiments include a dosage form that provides therapeutically effective levels of a first active agent and a second active agent in a mammal for an extended period of time following oral administration....

20060204580 - Biomimetic organic/inorganic composites, processes for their production, and methods of use: The subject invention concerns a composite comprising an organic fluid-swellable, fibrous matrix, such as collagen, and a mineral phase, such as calcium carbonate or phosphate mineral phase, for use as a biomimetic of bone. In another aspect, the subject invention concerns a process for making a composite involving the inclusion...

20060204581 - Biomimetic organic/inorganic composites, processes for their production, and methods of use: The subject invention concerns a composite comprising an organic fluid-swellable, fibrous matrix, such as collagen, and a mineral phase, such as calcium carbonate or phosphate mineral phase, for use as a biomimetic of bone. In another aspect, the subject invention concerns a process for making a composite involving the inclusion...

20060204583 - Chemoembolisation: A composition for chemoembolotherapy of solid tumours comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin....

20060204579 - Method for improving adsorption of a drug from ethylene oxide derivative: The present invention relates to a method for improving adsorption on the gastrointestinal mucous layers of one or more selected from polyethylene glycol, polyethylene oxide, and polyoxyethylene polypropylene copolymer wherein the average number of repeating oxyethylene units of one ethylene oxide chain length is 17 or greater. It is possible...

20060204582 - Multiple phase cross-linked compositions and uses thereof: The present invention is directed to pharmaceutical compositions, and method for preparing pharmaceutical compositions, comprising a cross-linked matrix physically entrapping at least one therapeutic agent. The matrix may comprise one or more phases in addition to an aqueous phase, such as a solid and/or oil phase. The matrix of the...

20060204584 - Materials and methods relating to polyions and substance delivery: Materials and method are disclose for delivering a desired substance to a target site, using a layered carrier in which the carrier and the substance together form at least three layers which associate by ionic interaction at the first pH, where at least one layer comprises a charge switch material...

20060204585 - Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them: In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacid are described. In another general aspect of the present invention, pharmaceutical formulations comprising both...

20060204586 - Time release calcium sulfate matrix for bone augmentation: A bone-growth stimulating composition for forming a resorbable implant, methods for making such a composition and a corresponding putty/paste material. In some embodiments of the invention, such a material includes a plurality of particles having a predetermined size and comprising a first calcium sulfate compound and a resorbable polymer in...

20060204588 - Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof: Described are nanoparticulate compositions of finasteride, dutasteride, tamsulosin hydrochloride, or a combination thereof. The formulations exhibit unexpectedly prolonged release and can be maintained in a depot for release to a patient for a period of up to six months....

20060204587 - Use of film coating as taste-masking coating of oral dosage forms: The present invention relates to the use of a film coating consisting of a) polyvinyl acetate b) hydrophilic additives c) other conventional coating ingredients d) and, where appropriate, a physiologically tolerated acid as taste-masking coating for oral dosage forms, and to a process for producing such dosage forms....

20060204589 - Bear derived isolate and method: A bear derived isolate found in denning black bears or black bears from which food has been withheld for at least two weeks when injected into another mammal produces reduced heart rate, reduced respiratory rate, reduced temperature, and a wakeful tranquility not unlike the phenomena of the denning black bear....

20060204590 - Formulations for the decontamination of toxic chemicals: A decontaminant composition comprising a peroxide; an organic co-solvent; an amine, which in reaction with the peroxide is a source of a perhydrolysis species; a phase transfer catalyst comprising at least one quaternary ammonium compound; a metal oxide catalyst; a chemical base; and at least one pH buffering compound....

20060204591 - Treatment of mucosal membranes: The invention relates to the use of one or more antimicrobial metals preferably selected from silver, gold, platinum, and palladium but most preferably silver, formed with atomic disorder, and preferably in a nanocrystalline form, for reducing inflammation or infection of the mucosal membrane. The antimicrobial metal may be formulated as,...

20060204592 - Chelated 8-hydroxyquinoline and use thereof in a method of treating epithelial lesions: A chelation complex including 8-hydroxyquinoline and zinc mixed with a carrier demonstrates therapeutic efficacy in treating lesions including cancerous lesions, precancerous lesions, cysts and warts....

20060204593 - Superoxide anion decomposing agent: A scavenger of superoxide anion or nitric oxide comprising finepowder of a transition metal such as platinum. The scavenger is preferably provided as an aqueous solution containing transition metal colloid at a ratio of 1 mM or less per 1,000 ml, and can efficiently eliminate excessive superoxide anions or nitric...

20060204594 - Inhibition of enzyme activity by adsorptive removal of controlling ions: Methods of preparing and using natural or synthetic zeolitic compositions therapeutically, so as to alleviate, cure, or even preclude human host disease attributable to exposure to bacteria within the Bacillus anthracis group: comprising, B. anthracis, B. cereus, B. Mycoide, and B. thurigiensis. Human exposure to the first member of the...

20060204595 - Antioxidant supplement composition for smokers and ex-smokers and method of producing thereof: An antioxidant supplement composition includes a mixture including 20-27% Glycyrrhiza uralensis, 2-6% Crataegus pinnatifida, 1-3% Ligusticum tenuissimum, 2-4% Acathopanax sessiliflorus, 2-5% Polygonum multiflorum, 3-6% Eugenia aromaticum, 8-10% Citrus reticulatae, 3-6% Raphani seed, 5-10% Platycodon grandiflorum, 21-26% Aloe arborescens, 18-20% Arctium lappa, 30-200 mg vitamin-C, and 1,500-20,000 IU β-carotene....

20060204596 - Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent: The present invention provides a composition of matter comprised of a mixture of two specific classes of compounds—Free-B-Ring flavonoids and flavans—referred to herein as UP736 for use in the prevention and treatment of diseases and conditions related to platelet aggregation and platelet-induced thrombosis. The invention further provides a novel composition...

20060204597 - Method and means for improving bowel health: A method and composition for improving one or more indicators of bowel health or metabolic health in a mammalian animal. This comprises the delivering to the gastrointestinal tract of the animal an effective amount of an altered wheat starch in the form of or derived from the grain of a...

20060204598 - Nicotine-alternative compositions and methods of producing such compositions: A method for producing a consumable nicotine-alternative composition includes measuring a quantity of a cigarette nicotine-alternative alkaloid and/or a larger quantity of lobeline. The quantities of cigarette nicotine-alternative alkaloid and/or lobeline are diluted into one or more successive intermediate solutions, a last of which constitutes a final solution. The final...

20060204599 - Dietary supplement and method of using same: A dietary supplement is provided whereby the daily administration of materials derived from the Acacia plants is provided orally to humans for the purpose of producing or maintaining weight loss as well as improving a person's physical performance and increasing the person's lean muscle mass. The Acacia materials include these...

20060204600 - Dragon's blood anti-viral materials and methods: The present invention provides for the administration of compounds, which can be synthesized or can be isolated from a Croton plant species for treating invertebrates or vertebrates, including humans, infected with Poxyiridae or Papillomavirinae. The present invention encompasses methods of using compounds synthesized or isolated from the Croton plant species,...

20060204601 - Formulations and methods for preventing and treating substance abuse and addiction: The invention relates to formulations and methods for preventing and/or treating substance abuse, addiction, withdrawal symptoms, and anticipation associated with substance abuse. In particular the invention relates to formulations comprising at least one processed Morinda citrifolia L. product, and methods comprising the administration of at least one processed Morinda citrifolia...

20060198783 - Porphyrin-based compounds for tumor imaging and photodynamic therapy: This invention describes a first report on the synthesis of certain 124I-labelled photosensitizers related to chlorines and bacteriochlorins with long wavelength absorption in the range of 660-800 nm. In preliminary studies, these compounds show a great potential for tumor detection by positron emission tomography (PET) and treatment by photodynamic therapy...

20060198784 - Methods of treatment using antibodies to neutrokine-alpha: The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV...

20060198785 - Bifunctional tridentate pyrazolyl containing ligands for re and tc tricarbonyl complexes: The present invention relates to a chelating agent of the general formula: (I), wherein m is 0 or 1; X is NR4 or S; Y is SR5, NHR5 or P(R5)2; R1 and R3 are the same or different and are selected from H, alkyl or aryl; R2 is H, COOH,...

20060198786 - Glycopeptide compositions: The invention include glycopeptides having a glycoside and a peptide covalently bound through an amide bond. The glycopeptides may also include a diagnostic or therapeutic agent bound to the glycopeptide. A metal, such as a radionuclide, may also be chelated to the glycopeptide. Specific embodiments of the invention relate to...

20060198787 - Biomarkers for predicting liver fibrosis treatment efficacy: The invention relates to methods for predicting or determining the efficacy of certain medical treatments, especially treatments for liver fibrosis. The methods of the invention include measuring interferon-induced ligands prior to initiating treatment and at some time following the initiation of treatment to predict the clinical outcome of the treatment....

20060198788 - Method of evaluating compound efficacious in treating obesity by using slc25a10: Evaluation of compounds including screening of therapeutic agents for obesity is performed utilizing expression levels of Slc25a10 gene or protein in a test tissue or a test cell, or utilizing the nature of Slc25a10 gene or protein. Examination of obesity is performed based on expression levels of Slc25a10 gene or...

20060198789 - Target validation assay: An method of determining whether a gene of interest is necessary for a tumor cell to maintain its tumorigenicity is disclosed. The method is useful for validation of cancer therapeutic targets in vivo, using shRNAs and tumor xenografts. The inducible shRNA method operates an in vivo RNAi competition assay....

20060198790 - Buccal, polar and non-polar spray containing ondansetron: Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide ondansetron for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, ondansetron, and optional flavoring agent; formulation II:...

20060198791 - Compositions and methods for bone formation and remodeling: The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk...

20060198793 - Antimicrobial polypeptide, nucleic acid, and methods of use: Antimicrobial compounds and compositions and uses thereof, including the treatment and prevention of bacterial infections are described. The compounds and compositions include lantibiotic polypeptides and the nucleic acid sequences encoding the polypeptides. The compounds and compositions are useful as antimicrobials in antibiotic pharmaceutical preparation and as an antimicrobial or antiseptic...

20060198792 - Recombinant protein comprising starch binding domain and use thereof: A recombinant protein is prepared comprising a polypeptide of interest and a starch binding domain (SBD). The said SBD is obtainable from glucoamylase of fungi genus Rhizopus. The said recombinant protein comprising the said SBD can be purified by contacting with an affinity matrix such as starch, the SBD binds...

20060198798 - Aqueous disinfectants and sterilants for skin and mucosal application: The present invention is drawn to disinfectant or sterilant compositions, which are human safe, e.g., food grade, food safe, or skin safe, etc. In one embodiment, an aqueous disinfectant or sterilant composition can comprise an aqueous vehicle, including water, from 0.001 wt % to 50 wt % of a peracid,...

20060198794 - Methods of whitening teeth: The present invention relates to improved dental compositions and methods for bleaching teeth. More specifically, this invention is directed towards hydrogen peroxide-containing compounds that are maintained at a substantially constant pH range of 6.0-10.0 during the tooth-bleaching procedure in the presence of a calcium chelating agent....

20060198795 - Multi-component oral care compositions: A multi-component oral care composition including two or more of: a preliminary component, an oral care component; and a finishing component. Two, three, four and more component compositions are formed hereby. Tooth whitening or cleaning is one use hereof....

20060198797 - Stand-alone or enhancer composition for oral care: A biological tissue care composition, such as an oral care composition, for enhancing the effects of whitening compositions. A solvent and surfactant is used with an alkaline builder and an optional saponifier. A method of use of such a composition includes use as a tooth cleaning composition. Alternatively the composition...

20060198796 - Whitening compositions and methods involving nitrogen oxide radicals: A tissue treatment composition comprising an effective amount of a nitric oxide, nitroxyl or nitrogen oxide composition for color effect of the tissue....

20060198799 - Tooth glossing or finishing compositions for oral care: A tooth glossing and/or finishing composition including one or both of a wax and an acidic neutralizer with an optional additive of a vegetable gelling agent....

20060198800 - Skin care compositions including hexapeptide complexes and methods of their manufacture: Skin care compositions disclosed herein include, at a minimum, safe and effective amounts of at least one wrinkle reduction agent, which is a hexapeptide, and a natural exfoliating complex. The skin care compositions provide natural skin exfoliation, reduce fine lines and wrinkles, and improve skin elasticity and firmness....

20060198801 - Aqueous nail varnish with improved film properties: A method of coating human nails with a polymer film. The method comprises steps of: (a) applying to the human nails a composition comprising: (i) a first polymer binder having Mw greater than 20,000 and a Tg less than 70° C.; (ii) a second polymer binder having Mw less than...

20060198802 - Cataplasm base and cataplasm using the same: The present invention provides a cataplasm base that exhibits high water content, having adhesive strength and shape-retaining property, that is free from paste seepage, and that prevents skin irritation and can be cleanly detached from the skin without paste residue; and a cataplasm using the same. The inventive cataplasm base...

20060198806 - Capsaicinoid decontamination compositions and methods of use: A therapeutic composition for inhibiting physiological responses elicited by exposure of skin to an irritant can be used to treat exposure to capsaicinoids or other chemical irritants. The therapeutic composition can include a carrier being present in an effective amount and form sufficient to be applied to skin and deliver...

20060198805 - Cosmetic and pharmaceutical masks for skin improvement: A method for skin improvement, comprising the application of a mask composed of two different fluid components, wherein the first component is adapted to be applied to contact skin, and second component is adapted to be applied to contact the first component, and whereby first and second components chemically react...

20060198807 - Hair grooming preparation: Provided are a rinse-off, non-dyeing type hair cosmetic composition containing (a) a polycarboxylic acid or salt thereof, (b) a hydroxymonocarboxylic acid or salt thereof, and (c) an organic solvent selected from aromatic alcohols, alkylene carbonates and polyols at a weight ratio satisfying 0.33≦[(a)+(b)]/(c)≦2.5, in which, the weight of each of...

20060198808 - Fiber product treating agent: wherein R11 represents a C15-23 alkyl or alkenyl group, A represents —CONH— or —NHCO—, R12 represents a C1-6 alkylene group, R13 and R14 respectively represent a C1-3 alkyl or hydroxyalkyl group, R15 represents H or C1-3 alkyl or hydroxyalkyl group, a denotes a number of 0 or 1 and X−...

20060198803 - Whitening system capable of delivering effective whitening action: The invention provides a foamable composition for tooth bleaching which can be a one- or two-component system. The system has at least one peroxide compound, and at least one foaming agent. The composition can also contain at least one source of calcium, strontium and mixtures thereof, at least one de-sensitizing...

20060198804 - Hair treatment comprising acrylic/silicone copolymer and cosmetic hair preparation containing the treatment: A hair treatment agent comprising an acryl/silicone copolymer (A) having at least one hydrolyzable silyl group per molecule and a hair cosmetic comprising the treatment agent are provided. The hair treatment agent and cosmetic comprising the same maintain good conditioning effect for a prolonged period of time....

20060198809 - Gamma-amino butyric acid composition: A composition for reducing skin wrinkles comprising a carrier and at least two neuromascular inhibitors. The composition can further include botanicals to further facilitate the reduction of fine lines, as well as emollients, thickeners and humectants....

20060198811 - Hair treatment compositions: A hair treatment composition that includes an aqueous formulation of leleshwa. The aqueous formulation of leleshwa is obtained by subjecting leleshwa to a steam distillation process to remove essential oils therefrom. The aqueous condensate phase from the steam distillation process is recovered and used as the aqueous formulation of leleshwa...

20060198810 - Plant based formulations for improving skin moisture, texture, and appearance: The present invention relates to formulations of ingredients that are useful for improving the appearance, texture and/or moisture of skin. In particular, the formulations of the present invention stimulate collagen, elastin, and lipid synthesis and/or inhibit or minimize the loss of collagen, elastin, and lipids in the skin. Additionally, the...

20060198812 - Liquid sealant and methods of use: The invention provides a composition useful for forming odor suppressing seals in waterless urinals. Methods of using the composition to form liquid seals as well as waterless urinals employing such liquid seals are further provided....

20060198816 - In situ bulking composition: The present invention relates to a hydrated, biocompatible tissue-augmentation compound and methodology for its implantation into mammalian tissue. The tissue-augmentation compound is comprised of: living tissue, optionally body derived fluids, and at least one NCO-terminated hydrophilic urethane prepolymer derived from an organic polyisocyanate, and oxyethylene-containing diols or polyols in which...

20060198815 - Pharmaceutical formulations for sustained release: Sustained delivery pharmaceutical compositions comprising a solid ionic complex of a pharmaceutically active compound and an ionic macromolecule are provided by the present invention. The pharmaceutical compositions of the invention allow for loading of high concentrations of pharmaceutically active compounds and for delivery of a pharmaceutically active compound for prolonged...

20060198814 - Anti-infectious hydrogel compositions: The present invention provides a hydrogel composition capable of preventing the intrusion of micro-organisms into body cavities or body openings of mammals comprising of a poly(N-vinyl lactam), a polysaccharide and water....

20060198813 - Substituted fullerene compositions and their use in treatment of shock: This patent discloses the use of substituted fullerenes in the treatment of shock. The substituted fullerenes comprise a fullerene core (Cn) and at least one of: (i) from 1 to 6 (>CX1X2) groups bonded to the fullerene core; (ii) from 1 to 18 —X3 groups bonded to the fullerene core;...

20060198817 - Materials and methods for preventing and treating microbe-mediated epithelial disorders: The present invention provides pharmaceutical compositions in the form of relatively high molecular weight biocompatible polymers such as polyethylene glycol, optionally supplemented with a protective polymer such ad dextran and/or essential pathogen nutrients such as L-glutantine. Also provided are methods for preventing or treating gut-derived sepsis attributable to intestinal pathogens...

20060198818 - Method for analyzing activated polyethylene glycol compounds: A chemical analysis method for the determination of RO(CH2CH2O)nH, RO(C2H4O)nA, and AO(C2H4O)nA in a mixture thereof, wherein R is an alkyl group, A is a functional group for coupling with a surface or a biologically active material or another thing of use and n is an interger greater than 10....

20060198820 - Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders: Methods for treatment of diseases, including human immunideficiency virus infection, are provided. The disease are treated by administering conjugates containing as a ligand a chemokine receptor targeting agents, such as a chemokine, and a targeted agent, such as a toxin....

20060198819 - Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest: This invention relates to novel compounds, methods for selective chemical conjugation of protractor molecules and the use thereof for diagnostic and/or therapeutic purposes....

20060198821 - Elevation of adenosine level by cytokine-induced expression of cd73: This invention concerns a method of inducing an elevated level of adenosine in an individual by administering to said individual an effective amount of either i) recombinant protein CD73 or ii) a cytokine or another factor-being capable of inducing endothelial CD73 expression, or a combination thereof. Furthermore, the invention concerns...

20060198822 - Treatment for multiple sclerosis: It is disclosed herein that particular forms of MS have significant pathogenetic differences both between each other and when compared to controls. In particular, CD127 is under-expressed in one form of MS but over-expressed in another form, relative both to each form of MS and to controls. Methods and compositions...

20060198823 - Compositions and methods for treating viral infections: The present invention provides methods of treating a virus infection, and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a coronavirus infection. The present invention further provides methods of reducing the risk that...

20060198824 - Treatments for flaviviridae virus infection: The present invention provides methods for treating infections, in a host, by viruses belonging to the Flaviviridae family, such as HCV, comprising administering an Ara-C homologue to the host....

20060198826 - Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof: The present invention relates to the compositions for a gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof. More specifically, the present invention provides a gene therapy of rheumatoid arthritis by preparing a recombinant vector that expresses a gene encoding an anti-angiogenic protein such...

20060198825 - Reagents, methods and systems to suppress phospholamban expression: The present invention relates to reagents, methods and systems to treat heart failure using small interfering RNA (siRNA) molecules targeted to phospholamban....

20060198829 - Differentiation of human mesenchymal stem cells to cardiac progenitor cells that promote cardiac repair: A method for treating a subject afflicted with a cardiac disorder, in vivo, comprises (i) inducing differentiation of a progenitor cell, in vitro, to a cardiogenic cell; and (ii) administering a therapeutically effective amount of the cardiogenic cell of step (i) to the subject, thereby treating the cardiac disorder in...

20060198828 - Methods and compositions for the inhibition of gene expression: The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers....

20060198827 - Engineering vascularized muscle tissue: A tissue engineered construct. The construct includes endothelial cells, muscle cells, and a three-dimensional support matrix on which the endothelial cells and the myoblasts are seeded....

20060198831 - Nitrosylation of protein sh groups and amino acid residues as a therapeutic modality: Nitrosylation of proteins and amino acid groups enables selective regulation of protein function, and also endows the proteins and amino acids with additional smooth muscle relaxant and platelet inhibitory capabilities. Thus, the invention relates to novel compounds achieved by nitrosylation of protein thiols. Such compounds include: S-nitroso-t-PA, S-nitroso-cathepsin; S-nitroso-lipoprotein; and...

20060198830 - Ubiquinone composition and a container for its convenient transport and storage: The present invention relates to a combination of a hermetically sealed, substantially air-tight container, and a quinone-containing composition disposed therein. The container of the present invention is adapted for the convenient transport, and storage of an effective amount of an active ingredient, for example, ubiquinone, ubiquinol or a mixture thereof,...

20060198832 - Peptide drugs for chronic lymphocytic leukemia (cll) and other cancers: The present invention provides a modified BAD peptide or peptidomimetic which includes an amino acid sequence having at least 60% amino acid identity with SEQ ID NO: 1, where the modified BAD peptide or peptidomimetic has enhanced affinity for Bcl-2 as compared to wild type BAD peptide (SEQ ID NO:...

20060198833 - Compositions and methods for targeting a polypeptide to the central nervous system: The invention provides a chimeric CNS targeting polypeptide having a BBB-receptor binding domain and a payload polypeptide domain. The chimeric CNS targeting polypeptide can have a BBB-receptor binding domain consisting of a receptor binding domain from ApoB, ApoE, aprotinin, lipoprotein lipase, PAI-1, pseudomonas exotoxin A, transferrin, α2-macroglobulin, insulin-like growth factor,...

20060198834 - Chaperonin 10 immunosuppression: The invention is directed to the use of cpn10 in transplantation and particularly to treatment and/or prevention of graft versus host disease. The invention provides a method of administration of cpn10 to a donor and/or recipient animal or cells, tissues or organs derived from the donor, although in a particularly...

20060198835 - Nucleic acid molecules encoding osteogenic proteins: Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth in mammals using the devices; 2) amino acid sequence data, amino acid composition, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, 3) methods of producing osteogenic proteins using...

20060198837 - Coagulation and fibrinolytic cascades modulator: A thromboplastin reagent comprises (i) TF, (ii) a phospholipid, and (iii) a polyP TFPI blocker....

20060198836 - Method of treating hit patients with argatroban: This invention relates to the improved methods of use of Argatroban in heparin-induced thombocytopenia....

20060198838 - Combination enzyme for cystic fibrosis: A stable preparation of digestive/pancreatic enzymes which can be readily formed into a dosage formulation is provided as a treatment of pancreatic insufficiency in persons having cystic fibrosis. The dosage formulation can be administered either by an oral preparation including, but not limited to, a microcapsule, mini-capsule, time released capsule,...

20060198839 - Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions: Type 1 diabetes mellitus and other conditions relating to inadequate insulin or diminished levels of insulin can be treated by administering a pancreatic islet cell regeneration agent and/or an agent that transforms pancreatic ductal cells to islet cells in combination with administration of an agent that selectively inhibits, blocks, or...

20060198840 - Molecules with extended half-lives, compositions and uses thereof: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant...

20060198841 - Drosophila g protein coupled receptors, nucleic acids, and methods related to the same: The present invention provides Drosophila melanogaster GPCR (DmGPCR) polypeptides and polynucleotides which identify and encode such a DmGPCR. In addition, the invention provides expression vectors, host cells, and methods for its production. The invention also provides methods for the identification of homologues in other species and of DmGPCR agonists/antagonists useful...

20060198842 - Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors: Screening methods for identifying compounds that bind to or activate corticotropin releasing factor2 receptors (CRF2R) and regulate or potentially regulate skeletal muscle mass or function in vivo are disclosed. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRF2Rs or of CRF2R signal transduction...

20060198844 - Bone morphogenetic protein-2 in the treatment and diagnosis of cancer: The present invention pertains to the use of BMP-2, which is overexpressed in most common cancers, as 1) a target for cancer treatment therapies and 2) a means to diagnose cancer. The therapeutic component of this invention involves administering to a patient a composition that inhibits bone morphogenetic-2 activity. Such...

20060198843 - Treatment with anti-erbb2 antibodies and chemotherapeutic agents: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and chemotherapeutic agents....

20060198846 - Combinations for the treatment of diseases involving angiogenesis: Compositions for the inhibition of the formation of new vasculature by angiogenesis are provided comprising the combination of a vasculature damaging agent and an inhibitor of the formation or action of nitric oxide in mammalian systems. There are also provided the use of said combinations in medicaments and kits of...

20060198847 - Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis: A method of modulating angiogenesis in a vertebrate subject, the method comprising administering to the vertebrate subject an ECRTP/DEP-1 activity-modulating amount of a composition, whereby an ECRTP/DEP-1 within the vertebrate subject is contacted by the composition; and modulating angiogenesis through the contacting of the ECRTP/DEP-1 with the composition. Optionally, the...

20060198845 - Monoclonal antibody against human hepatoma and use thereof: The present invention provides a monoclonal antibody MF4C4 against human hepatoma marker antigen. This monoclonal antibody is characterized by high specifically binding to the hepatoma antigen. The present invention also provides MF4C4 immunoglobulins, and the fragments and immunological conjugates thereof, and pharmaceutical compositions containing the immunoglobulins, fragments or immunological conjugates....

20060198848 - Methods and compositions for treating herpes infections: A method of treatment or prophylaxis of herpes infections and associated disease states by administration of compositions comprising immunoglobulins. Methods comprising intravenous and topical administration of immunoglobulins are provided....

20060198849 - Preparation method of igy for preventing and cure mouth disease and the toothpaste base on the igy: The present invention relates to a preparation method of IgY for preventing and cure mouth disease, and a safe toothpaste containing the IgY....

20060198850 - Pharmaceutical formulation and a method of making same: The methods of the present invention and the formulations made from those methods, allow the stable integration of multiple actives within a single formulation. The solubilisation of an active in a suitable solvent and the subsequent adsorption onto a sorbing medium provide effective protection for the active from any adverse...

20060198851 - Humanized abeta antibodies for use in improving cognition: The invention provides improved agents and methods for treatment of diseases associated with beta amyloid (Aβ). Preferred agents include antibodies, e.g., humanized antibodies specific for Aβ....

20060198852 - Collagen-binding mscramms of bacillus anthracis and uses therefor: The present invention provides cell wall anchored proteins of Bacillus anthracis representative of the MSCRAMM family of proteins and DNAs encoding the same. Also provided are collagen-binding peptides comprising the collagen-binding region A of the cell wall anchored proteins and DNAs encoding these peptides. Further provided are pharmaceutical compositions and...

20060198853 - Papilloma virus capsomere vaccine formulations and methods of use: Vaccine formulations comprising viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed....

20060198854 - Vector platforms derived from the alphavirus vaccines: Nucleic acid molecules and vector platforms derived from human virus vaccines, for example the alphavirus vaccines, including the TC-83 human vaccine, are disclosed. These vector platforms can provide for expression of a heterologous protein or nucleic acid in animal or human cells. In preferred embodiments, the nucleic acid molecules and...

20060198855 - Uses of dc-sign and dc-signr for inhibiting hepatitis c virus infection: This invention provides a method of inhibiting HCV infection of a cell susceptible to HCV infection which comprises contacting the cell with an amount of a compound effective to inhibit binding of an HCV envelope glycoprotein to a DC-SIGN protein present on the surface of the cell, so as to...

20060198856 - Ibuprofen suspension stabilized with docusate sodium: A stabilized aqueous pharmaceutical ibuprofen composition of ibuprofen stabilized with a stabilizing effective amount of docusate sodium....

20060198859 - Compositions with a depot effect for controlling microorganisms: The invention relates to compositions for controlling microorganisms comprising an effective content of mixtures of fatty acid esters of a polyol and of short-chain monocarboxylic acids and/or salts thereof....

20060198861 - Flexible ultra-low permeability transport system and method: A system and method for long-term storage of a commodity in a weight range of 10-2000 kilograms includes hermetic sealing of an ultra-low permeability, easily transportable, flexible long-term storage container. The long-term storage container may also be treated using non-toxic insect repellents of botanical origin or using a synthetic pyrethroid....

20060198857 - Insect control system: A system for controlling insects, which system includes a substrate in the form of an elongate tape having thereon a plurality of target zones spaced apart at predetermined intervals along a first surface of the substrate, each target zone including an insect attractant and/or an insect control agent....

20060198860 - Synergistic blends of monoterpenes for mountain pine beetle pheromones: This invention relates to compositions and methods of using blends of two or more monoterpenes as synergists for attractive pheromones of the mountain pine beetle, Dendroctonus ponderosae. When deployed in effective amounts in traps, on pine trees or in the vicinity of pine trees, these blends will increase the numbers...

20060198858 - System and method for effectively controlling household allergens: A system and method of effectively controlling household allergens or pests such as house dust mites or bed mites. The system comprises a container fluidly coupled to a covering, wherein the covering surrounds the household pests' environment. The method for effectively controlling the household pests comprises: surrounding or coupling a...

20060198862 - Snail baiting agent: in which R stands for C1-C10 alkyl, which is equally or differently substituted once or several times by PO3H2, OH, NH2, CN, halogen, C1-C8 alkylamine or C2-C16 dialkylamine and is optionally interrupted by 1-6 heteroatoms from the series N, O, S, P, wherein heteroatoms are not directly coupled to one...

20060198864 - Biointerface membranes incorporating bioactive agents: A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen...

20060198863 - Ceramic composition for filling bone defects: The invention is directed toward a formable ceramic composition for application to a bone defect site which comprises a ceramic compound of beta tricalcium phosphate particles. The particle size ranges from about 40 microns to 500 microns and is mixed in a hydrogel carrier containing citric acid buffer, the hydrogel...

20060198865 - Microencapsulated compositions for endoluminal tissue engineering: A tissue engineering composition adapted for application to an interior surface of a body lumen of a patient. The composition comprises (a) a carrier medium that is adapted to flow and to stably adhere the composition to the body lumen and (b) microcapsules, which are dispersed within the carrier medium...

20060198866 - Thermoplastic fluoropolymer-coated medical devices: A medical device provided with at least a partial surface coating of a thermoplastic copolymer of tetrafluoroethylene and perfluoroalkylvinylether that is free of cross-linking monomers and curing agents. The fluoropolymer coating is preferably an amorphous thermoplastic, is highly inert and biocompatible, has elastomeric characteristics that provide desirable mechanical properties such...

20060198869 - Bioabsorable medical devices: A medical device that is at least partially formed of a bioabsorbable metal alloy that includes a majority weight percent of magnesium and at least one metal selected of calcium, rare earth metal, yttrium, zinc, and/or zirconium....

20060198868 - Biodegradable coating compositions comprising blends: The invention provides devices for treatment of a patient, wherein at least a portion of the device is provided with a biodegradable coating composed of a blend of bioactive agent and at least two biodegradable polymers or copolymers. The invention further provides methods of treatment utilizing the devices....

20060198867 - Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy: Systems and compositions comprising zotarolimus that are safer, more effective and produce less inflammation than rapamycin and paclitaxel systems are disclosed. Medical devices comprising supporting structures capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient can contain one or more therapeutic agents or substances,...

20060198870 - Medical devices containing rapamycin analogs: s

20060198871 - Methods for treating neovascularization and intravitreal implants: Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer....

20060198872 - Plant based dietary supplement for improving the duration and quality of sleep: The present invention relates to compositions for treating insomnia or sleeplessness. The compositions of the present invention comprise jujube extract and at least one of white peony extract, radix polygala extract, and passion flower extract. The extracts used in the compositions of the present invention bind strongly to GABA receptors...

20060198876 - Aqueous disinfectants and sterilants and related delivery systems: The present invention is drawn to disinfectant or sterilant compositions and associated methods of use. In one embodiment, an aqueous disinfectant or sterilant composition can comprise an aqueous vehicle, including water, from 0.001 wt % to 50 wt % of a peracid, and from 0.001 wt % to 25 wt...

20060198875 - Core assembly for essential oil: A core assembly for essential oil includes an oil suction member, and a core head mounted on and connected to a top end of the oil suction member. Thus, the core head is combined with the oil suction member, so that the essential oil absorbed by the capillary effect the...

20060198877 - Medical instrument for autologous chondrocyte transplantation: A medical instrument for autologous chondrocyte transplantation comprises a stamp for introducing an implantable nonwoven into a cartilage. This stamp has, on a distal end face, at least one opening to which an underpressure can be applied....

20060198873 - Orally dissolving films: Rapidly dissolving, oral film preparations for rapid release of an active agent in the oral cavity, in particular, rapidly dissolving oral films comprising a nicotine active which achieve good transbuccal absorption and provide nicotine craving relief to an individual are disclosed herein....

20060198878 - Preparation in film form for biphasic release of pharmaco-logically active or other substances: A polymer-based preparation in film form for biphasic release of substances present therein to liquid surroundings, is characterized in that the preparation comprises at least two polymer matrix layers which differ in terms of their construction from polymers, with release taking place rapidly from one of the layers, and release...

20060198874 - Warming and cooling devices made of hypoallergenic organic materials: Therapeutic devices for warming and/or cooling limbs, joints, and body parts, to relieve pain or discomfort, are made of entirely hypo-allergenic materials, such as organically grown cotton fabric and flaxseed. Flaxseed can be heated effectively and safely in a microwave oven, and has a relatively high “specific heat”, allowing it...

20060198879 - Patch material for ionic medicine administration: The present invention discloses a patch for use in administration of an ionic medicine into a living body by infiltration of the ionic medicine into the living body through the living body surface without voltage application, characterized in that the patch comprises an ion-exchange membrane having a surface roughness (Rz)...

20060198880 - Ultraviolet-shielding type patch: e

20060198881 - Tamper resistant transdermal dosage form: The invention comprises a transdermal dosage form comprising an active agent component comprising an active agent and an adverse agent component comprising an adverse agent, wherein the active agent component defines at least one channel extending substantially there through....

20060198882 - Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer: The present invention concerns a stable lipid assembly comprising a biologically active lipid having a hydrophobic region and a polar headgroup, wherein the atomic mass ratio between the headgroup and hydrophobic region is less than 0.3, and a lipopolymer having a hydrophobic lipid region and a polymer headgroup, wherein the...

20060198883 - Compositions and methods for the treatment of anorectal disorders: Compositions and methods for the treatment of anorectal disorders are provided in which certain combinations of NO donors, PDE inhibitors, superoxide (O2−) scavengers, β-adrenergic agonists, cAMP-dependent protein kinase activators, α1-adrenergic antagonists, L-type Ca2+ channel blockers, estrogens, ATP-sensitive K+ channel activators and smooth muscle relaxants are used....

20060198884 - Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane: The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following...

20060198885 - Oral pharmaceutical composition: An oral pharmaceutical composition having reduced bitterness comprising therapeutically effective amounts of cetirizine or its pharmaceutically acceptable salts, alkaline earth oxide and a pharmaceutically acceptable carrier comprising a disintegrant wherein the composition disintegrates rapidly in the oral cavity....

20060198887 - Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof: An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch....

20060198886 - Medicament having coated methenamine combined with acidifier: A solid pharmaceutical medicament has a coated methenamine compound in combination with an urinary acidifier....

20060198888 - Tolperisone-containing pharmaceutical preparation with controllable active-substance release for oral administration: The invention relates to a tolperisone-containing pharmaceutical preparation with controllable active-substance release for oral administration, characterised in that the active substance tolperisone and/or a pharmaceutical salt thereof is embedded in a pharmaceutically compatible material. By selecting the pharmaceutically compatible materials in the preparation and accordingly in the coating of a...

20060198889 - Roflumilast and integrin inhibitor combination and treatement method: The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a therapeutically active amount of roflumilast, or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of N-(2-chloro-6-methylbenzoyl)-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine-2-(diethylamino)ethyl ester, or a pharmaceutically acceptable thereof, and one or more pharmaceutically acceptable excipients. These novel solid pharmaceutical dosage forms...

20060198890 - Durable film coating compositions having sustained slow-release capability, and methods of use therefor: Provided is a slow-release delivery vehicle for delivering at least one active ingredient into a film coating, comprising a population of stable, homogeneously-dispersed, porous polymeric or co-polymeric beads having a network of pores, wherein the at least one active ingredient is held within the bead particles and within the network...

20060198892 - Polymeric systems for controlled drug therapy: Polymeric compositions containing a high percentage of bound alkyl ether segments provide matrices and membranes for the controlled release of drugs and medicinal agents. The polymeric compositions are prepared by the polymerization of ethylenically unsaturated alkyl ether containing monomers. Copolymers of ethylenically unsaturated alkyl ether containing monomers with co-monomers are...

20060198891 - Solid formulations of liquid biologically active agents: The instant invention relates to a solid product comprising a liquid biologically active agent which is intimately associated to a stabilizing agent; particularly a solid product that can be reconstituted to a clear, stable, stabilized nanodispersion or loaded micelles comprising a polymer as a stabilizing agent and a liquid, preferably...

20060198896 - Aerosol and injectable formulations of nanoparticulate benzodiazepine: Described are nanoparticulate formulations of a benzodiazepine, such as lorazepam, that does not require the presence of polyethylene glycol and propylene glycol as stabilizers, and methods of making and using such formulations. The formulations are particularly useful in aerosol and injectable dosage forms, and comprise nanoparticulate benzodiazepine, such as lorazepam,...

20060198893 - Aqueous dispersion comprising stable nanoparticles of a water-insoluble pyrrole carboxamide and excipient like middle chain triglycerides: s

20060198895 - Azithromycin powder for oral suspension compositions: Non-caking azithromycin powder for oral suspension compositions and methods of making such compositions are disclosed. The compositions comprise a hydrated buffer, preferably a hydrate of sodium phosphate such as tribasic sodium phosphate dodecahydrate....

20060198894 - Stabilized, solid-state polypeptide particles: The present invention includes solid-state polypeptide particles containing a polypeptide material that is stabilized against degradation at temperatures that approximate or exceed physiological conditions. In each embodiment, the polypeptide particles of the present invention incorporate a polypeptide material that is stabilized against degradation by one or more stabilizing conditions. Because...

20060198897 - Polycationic peptide coatings and methods of coating implantable medical devices: Coatings for medical devices which include polycationic peptides such as L-arginine and methods for fabricating the coatings are disclosed....

20060198898 - Method for preventing ulceration or irritation of mucosa: The present invention provides novel compositions and methods for protecting and promoting cell growth and restoring physiological structure and function to mucosal tissue of the body, especially mucosa in the gastrointestinal tract. The composition can be used as a pharmaceutical or nutraceutical to treat a gastrointestinal disorder or to promote...

20060198900 - Bioactive agent compositions for repair of cell injuries: A method for prophylactically treating a gastrointestinal disorder or skin ailment in a mammal through the administration of an enhanced bioactive agent composition comprising a bioactive agent and at least one of a soy product, licorice product, or sodium bicarbonate (depending upon the indication to be treated) is provided according...

20060198899 - Supplemental dietary composition for supporting muscle growth, recovery and strength: Methods and compositions for the purposes muscle growth, recovery and/or strength are set forth. The compositions may include, but are not limited to, creatine monohydrate, glutamine alpha-ketoglutarate, glutamine, glutamine peptides, L-glutamine, L-leucine, L-valine, L-isoleucine and guar gum. The supplemental dietary compositions may be suitable for persons seeking to improve strength...

20060198901 - Drugs, bio-affecting and body treating compositions: Micro-clustered water compositions of bio-affecting agents, body-treating agents, and adjuvants or carriers, pharmaceutical and diagnostic compositions thereof. Methods of using the compositions involving administering them ex vivo to cells, tissues or organs, or in vivo to living bodies; and methods of making the compositions....

20060198903 - Antimicrobial coating methods: The invention is directed to efficient methods for depositing highly adherent anti-microbial materials onto a wide range of surfaces. A controlled cathodic arc process is described, which results in enhanced adhesion of silver oxide to polymers and other surfaces, such as surfaces of medical devices. Deposition of anti-microbial materials directly...

20060198902 - Topical medicament and method of use: A topical medicament, and associate method of use, for the treatment of dermatologic conditions in both humans and animals is provided. The medicament includes a mixture of Vitamin A, Vitamin D, Vitamin E, lanolin, petroleum jelly, colloidal silver, ti tree oil, zinc oxide and corn starch in appropriate proportions. Ingredient...

20060198906 - Compositions and method to increase serum levels of hdl cholesterol and lower the risk of cardiovascular disease: The invention provides a method for increasing serum high density lipoprotein (HDL) cholesterol levels, and lowering serum levels of Lipoprotein (a) and C-reactive protein, as well as a suitable composition comprising a) a vegetable protein, b) a natural antioxidant compound, c) a natural anti-inflammatory compound, d) a bioavailable source of...

20060198904 - Methods for inhibiting allergic inflammation and other responses initiated by pollens, molds, and other non-animal derived allergens: Disclosed are methods for treating or preventing allergic inflammation in a subject and methods for treating or preventing one or more symptoms of allergic inflammation in a subject. The methods include administering to the subject a compound which inhibits reactive oxygen species. Also disclosed are methods for reducing a non-animal-derived...

20060198905 - Pharmaceutical compositions comprising an extract of euphorbia prostrata: The invention relates to novel compositions comprising of an extract of the plant Euphorbia prostrata, particularly with pharmaceutically acceptable carrier(s)/base(s), optionally with additional therapeutic agent(s) useful for the treatment of anorectal disease and colonic diseases such as hemorrhoids, fissures, cracks, fistulas, abscesses, inflammatory bowel disease, and the like. The nove(...

20060198907 - Pharmaceutical, therapeutic, and dietary compositions derived from lagerstroemia speciosa l. plant: The present invention relates to pharmaceutical, therapeutic, and dietary compositions derived from leaf of the Lagerstroemia speciosa L. plant and the novel extraction processes used to produce these controlled blends of varying composition with respect to corosolic acid, gallotannins, ellagitannins, and valoneic acid dilactone. Embodiments of the invention include an...

20060198908 - Ginseng preparation using vinegar and process for thereof: The present invention relates to a ginseng preparation using vinegar and a process for preparing the same, more particularly to a ginseng preparation comprising high concentrations of ginsenosides (Rg3, Rg5, and Rh1), which are generated by heat and exist only small amounts in red ginseng comprising various organic acids of...

20060198909 - Process to lose weight, drain unwanted body fats and other toxins: A method is disclosed comprising placing about thirty-two fluid ounces of water into a receptacle, placing the receptacle with water on a burner and bringing the water to a boil, ceasing to heat the water, adding about one teaspoonful or five grams of tea beverage flavorant to the water; and...

20060198910 - Method for processing vegetable raw materials: The inventive method for processing vegetable raw materials consisting in organic solvent-extracting said materials, isolating it by retention which is associated with cooling and wax filtration, separating free oxides from the thus obtained solution of extractive substances by alkali solution action, dividing the obtained neutralised solution into a neutral substance...

20060198911 - Foodstuff produced with extract of peanut stem for regulating blood sugar: A foodstuff is produced through extracting healthful and medicinal compositions contained in peanut stems. The food stuff may be in the form of liquid, cream, powder, tablet or capsule for users to drink, eat, or swallow conveniently. The foodstuff produced with extract of peanut stem contains not only nutrient that...

20060198912 - Topical treatment compositions: A dermatological treatment composition that includes an oil extract of leleshwa. The oil extract of leleshwa can be used alone or combined together with other ingredients in liquid, ointment, salve, gel, cream or foam formulations to treat a variety of dermatological conditions, including athlete's foot, verruca, shingles, atopic dermatitis, and...

20060198913 - Method of improvement of blood circulation: A method for the enhancement of the blood microcirculation and/or the oxygen supply of the skin of the lower extremities in a patient in need thereof, which method comprises administering an effective amount of an aqueous extract of red vine leaves to the patient....

20060198914 - Use of rutin and isoharmnetin for treating depressive states and depression and other emotion disorders: The present invention relates to the use of rutin and isorhamnetin for the treatment of episodes of depression and depressive diseases as well as in case of other affective disorders and preliminary stages thereof....

20060198783 - Porphyrin-based compounds for tumor imaging and photodynamic therapy: This invention describes a first report on the synthesis of certain 124I-labelled photosensitizers related to chlorines and bacteriochlorins with long wavelength absorption in the range of 660-800 nm. In preliminary studies, these compounds show a great potential for tumor detection by positron emission tomography (PET) and treatment by photodynamic therapy...

20060198784 - Methods of treatment using antibodies to neutrokine-alpha: The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV...

20060198785 - Bifunctional tridentate pyrazolyl containing ligands for re and tc tricarbonyl complexes: The present invention relates to a chelating agent of the general formula: (I), wherein m is 0 or 1; X is NR4 or S; Y is SR5, NHR5 or P(R5)2; R1 and R3 are the same or different and are selected from H, alkyl or aryl; R2 is H, COOH,...

20060198786 - Glycopeptide compositions: The invention include glycopeptides having a glycoside and a peptide covalently bound through an amide bond. The glycopeptides may also include a diagnostic or therapeutic agent bound to the glycopeptide. A metal, such as a radionuclide, may also be chelated to the glycopeptide. Specific embodiments of the invention relate to...

20060198787 - Biomarkers for predicting liver fibrosis treatment efficacy: The invention relates to methods for predicting or determining the efficacy of certain medical treatments, especially treatments for liver fibrosis. The methods of the invention include measuring interferon-induced ligands prior to initiating treatment and at some time following the initiation of treatment to predict the clinical outcome of the treatment....

20060198788 - Method of evaluating compound efficacious in treating obesity by using slc25a10: Evaluation of compounds including screening of therapeutic agents for obesity is performed utilizing expression levels of Slc25a10 gene or protein in a test tissue or a test cell, or utilizing the nature of Slc25a10 gene or protein. Examination of obesity is performed based on expression levels of Slc25a10 gene or...

20060198789 - Target validation assay: An method of determining whether a gene of interest is necessary for a tumor cell to maintain its tumorigenicity is disclosed. The method is useful for validation of cancer therapeutic targets in vivo, using shRNAs and tumor xenografts. The inducible shRNA method operates an in vivo RNAi competition assay....

20060198790 - Buccal, polar and non-polar spray containing ondansetron: Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide ondansetron for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, ondansetron, and optional flavoring agent; formulation II:...

20060198791 - Compositions and methods for bone formation and remodeling: The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk...

20060198793 - Antimicrobial polypeptide, nucleic acid, and methods of use: Antimicrobial compounds and compositions and uses thereof, including the treatment and prevention of bacterial infections are described. The compounds and compositions include lantibiotic polypeptides and the nucleic acid sequences encoding the polypeptides. The compounds and compositions are useful as antimicrobials in antibiotic pharmaceutical preparation and as an antimicrobial or antiseptic...

20060198792 - Recombinant protein comprising starch binding domain and use thereof: A recombinant protein is prepared comprising a polypeptide of interest and a starch binding domain (SBD). The said SBD is obtainable from glucoamylase of fungi genus Rhizopus. The said recombinant protein comprising the said SBD can be purified by contacting with an affinity matrix such as starch, the SBD binds...

20060198798 - Aqueous disinfectants and sterilants for skin and mucosal application: The present invention is drawn to disinfectant or sterilant compositions, which are human safe, e.g., food grade, food safe, or skin safe, etc. In one embodiment, an aqueous disinfectant or sterilant composition can comprise an aqueous vehicle, including water, from 0.001 wt % to 50 wt % of a peracid,...

20060198794 - Methods of whitening teeth: The present invention relates to improved dental compositions and methods for bleaching teeth. More specifically, this invention is directed towards hydrogen peroxide-containing compounds that are maintained at a substantially constant pH range of 6.0-10.0 during the tooth-bleaching procedure in the presence of a calcium chelating agent....

20060198795 - Multi-component oral care compositions: A multi-component oral care composition including two or more of: a preliminary component, an oral care component; and a finishing component. Two, three, four and more component compositions are formed hereby. Tooth whitening or cleaning is one use hereof....

20060198797 - Stand-alone or enhancer composition for oral care: A biological tissue care composition, such as an oral care composition, for enhancing the effects of whitening compositions. A solvent and surfactant is used with an alkaline builder and an optional saponifier. A method of use of such a composition includes use as a tooth cleaning composition. Alternatively the composition...

20060198796 - Whitening compositions and methods involving nitrogen oxide radicals: A tissue treatment composition comprising an effective amount of a nitric oxide, nitroxyl or nitrogen oxide composition for color effect of the tissue....

20060198799 - Tooth glossing or finishing compositions for oral care: A tooth glossing and/or finishing composition including one or both of a wax and an acidic neutralizer with an optional additive of a vegetable gelling agent....

20060198800 - Skin care compositions including hexapeptide complexes and methods of their manufacture: Skin care compositions disclosed herein include, at a minimum, safe and effective amounts of at least one wrinkle reduction agent, which is a hexapeptide, and a natural exfoliating complex. The skin care compositions provide natural skin exfoliation, reduce fine lines and wrinkles, and improve skin elasticity and firmness....

20060198801 - Aqueous nail varnish with improved film properties: A method of coating human nails with a polymer film. The method comprises steps of: (a) applying to the human nails a composition comprising: (i) a first polymer binder having Mw greater than 20,000 and a Tg less than 70° C.; (ii) a second polymer binder having Mw less than...

20060198802 - Cataplasm base and cataplasm using the same: The present invention provides a cataplasm base that exhibits high water content, having adhesive strength and shape-retaining property, that is free from paste seepage, and that prevents skin irritation and can be cleanly detached from the skin without paste residue; and a cataplasm using the same. The inventive cataplasm base...

20060198806 - Capsaicinoid decontamination compositions and methods of use: A therapeutic composition for inhibiting physiological responses elicited by exposure of skin to an irritant can be used to treat exposure to capsaicinoids or other chemical irritants. The therapeutic composition can include a carrier being present in an effective amount and form sufficient to be applied to skin and deliver...

20060198805 - Cosmetic and pharmaceutical masks for skin improvement: A method for skin improvement, comprising the application of a mask composed of two different fluid components, wherein the first component is adapted to be applied to contact skin, and second component is adapted to be applied to contact the first component, and whereby first and second components chemically react...

20060198807 - Hair grooming preparation: Provided are a rinse-off, non-dyeing type hair cosmetic composition containing (a) a polycarboxylic acid or salt thereof, (b) a hydroxymonocarboxylic acid or salt thereof, and (c) an organic solvent selected from aromatic alcohols, alkylene carbonates and polyols at a weight ratio satisfying 0.33≦[(a)+(b)]/(c)≦2.5, in which, the weight of each of...

20060198808 - Fiber product treating agent: wherein R11 represents a C15-23 alkyl or alkenyl group, A represents —CONH— or —NHCO—, R12 represents a C1-6 alkylene group, R13 and R14 respectively represent a C1-3 alkyl or hydroxyalkyl group, R15 represents H or C1-3 alkyl or hydroxyalkyl group, a denotes a number of 0 or 1 and X−...

20060198803 - Whitening system capable of delivering effective whitening action: The invention provides a foamable composition for tooth bleaching which can be a one- or two-component system. The system has at least one peroxide compound, and at least one foaming agent. The composition can also contain at least one source of calcium, strontium and mixtures thereof, at least one de-sensitizing...

20060198804 - Hair treatment comprising acrylic/silicone copolymer and cosmetic hair preparation containing the treatment: A hair treatment agent comprising an acryl/silicone copolymer (A) having at least one hydrolyzable silyl group per molecule and a hair cosmetic comprising the treatment agent are provided. The hair treatment agent and cosmetic comprising the same maintain good conditioning effect for a prolonged period of time....

20060198809 - Gamma-amino butyric acid composition: A composition for reducing skin wrinkles comprising a carrier and at least two neuromascular inhibitors. The composition can further include botanicals to further facilitate the reduction of fine lines, as well as emollients, thickeners and humectants....

20060198811 - Hair treatment compositions: A hair treatment composition that includes an aqueous formulation of leleshwa. The aqueous formulation of leleshwa is obtained by subjecting leleshwa to a steam distillation process to remove essential oils therefrom. The aqueous condensate phase from the steam distillation process is recovered and used as the aqueous formulation of leleshwa...

20060198810 - Plant based formulations for improving skin moisture, texture, and appearance: The present invention relates to formulations of ingredients that are useful for improving the appearance, texture and/or moisture of skin. In particular, the formulations of the present invention stimulate collagen, elastin, and lipid synthesis and/or inhibit or minimize the loss of collagen, elastin, and lipids in the skin. Additionally, the...

20060198812 - Liquid sealant and methods of use: The invention provides a composition useful for forming odor suppressing seals in waterless urinals. Methods of using the composition to form liquid seals as well as waterless urinals employing such liquid seals are further provided....

20060198816 - In situ bulking composition: The present invention relates to a hydrated, biocompatible tissue-augmentation compound and methodology for its implantation into mammalian tissue. The tissue-augmentation compound is comprised of: living tissue, optionally body derived fluids, and at least one NCO-terminated hydrophilic urethane prepolymer derived from an organic polyisocyanate, and oxyethylene-containing diols or polyols in which...

20060198815 - Pharmaceutical formulations for sustained release: Sustained delivery pharmaceutical compositions comprising a solid ionic complex of a pharmaceutically active compound and an ionic macromolecule are provided by the present invention. The pharmaceutical compositions of the invention allow for loading of high concentrations of pharmaceutically active compounds and for delivery of a pharmaceutically active compound for prolonged...

20060198814 - Anti-infectious hydrogel compositions: The present invention provides a hydrogel composition capable of preventing the intrusion of micro-organisms into body cavities or body openings of mammals comprising of a poly(N-vinyl lactam), a polysaccharide and water....

20060198813 - Substituted fullerene compositions and their use in treatment of shock: This patent discloses the use of substituted fullerenes in the treatment of shock. The substituted fullerenes comprise a fullerene core (Cn) and at least one of: (i) from 1 to 6 (>CX1X2) groups bonded to the fullerene core; (ii) from 1 to 18 —X3 groups bonded to the fullerene core;...

20060198817 - Materials and methods for preventing and treating microbe-mediated epithelial disorders: The present invention provides pharmaceutical compositions in the form of relatively high molecular weight biocompatible polymers such as polyethylene glycol, optionally supplemented with a protective polymer such ad dextran and/or essential pathogen nutrients such as L-glutantine. Also provided are methods for preventing or treating gut-derived sepsis attributable to intestinal pathogens...

20060198818 - Method for analyzing activated polyethylene glycol compounds: A chemical analysis method for the determination of RO(CH2CH2O)nH, RO(C2H4O)nA, and AO(C2H4O)nA in a mixture thereof, wherein R is an alkyl group, A is a functional group for coupling with a surface or a biologically active material or another thing of use and n is an interger greater than 10....

20060198820 - Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders: Methods for treatment of diseases, including human immunideficiency virus infection, are provided. The disease are treated by administering conjugates containing as a ligand a chemokine receptor targeting agents, such as a chemokine, and a targeted agent, such as a toxin....

20060198819 - Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest: This invention relates to novel compounds, methods for selective chemical conjugation of protractor molecules and the use thereof for diagnostic and/or therapeutic purposes....

20060198821 - Elevation of adenosine level by cytokine-induced expression of cd73: This invention concerns a method of inducing an elevated level of adenosine in an individual by administering to said individual an effective amount of either i) recombinant protein CD73 or ii) a cytokine or another factor-being capable of inducing endothelial CD73 expression, or a combination thereof. Furthermore, the invention concerns...

20060198822 - Treatment for multiple sclerosis: It is disclosed herein that particular forms of MS have significant pathogenetic differences both between each other and when compared to controls. In particular, CD127 is under-expressed in one form of MS but over-expressed in another form, relative both to each form of MS and to controls. Methods and compositions...

20060198823 - Compositions and methods for treating viral infections: The present invention provides methods of treating a virus infection, and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a coronavirus infection. The present invention further provides methods of reducing the risk that...

20060198824 - Treatments for flaviviridae virus infection: The present invention provides methods for treating infections, in a host, by viruses belonging to the Flaviviridae family, such as HCV, comprising administering an Ara-C homologue to the host....

20060198826 - Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof: The present invention relates to the compositions for a gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof. More specifically, the present invention provides a gene therapy of rheumatoid arthritis by preparing a recombinant vector that expresses a gene encoding an anti-angiogenic protein such...

20060198825 - Reagents, methods and systems to suppress phospholamban expression: The present invention relates to reagents, methods and systems to treat heart failure using small interfering RNA (siRNA) molecules targeted to phospholamban....

20060198829 - Differentiation of human mesenchymal stem cells to cardiac progenitor cells that promote cardiac repair: A method for treating a subject afflicted with a cardiac disorder, in vivo, comprises (i) inducing differentiation of a progenitor cell, in vitro, to a cardiogenic cell; and (ii) administering a therapeutically effective amount of the cardiogenic cell of step (i) to the subject, thereby treating the cardiac disorder in...

20060198828 - Methods and compositions for the inhibition of gene expression: The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers....

20060198827 - Engineering vascularized muscle tissue: A tissue engineered construct. The construct includes endothelial cells, muscle cells, and a three-dimensional support matrix on which the endothelial cells and the myoblasts are seeded....

20060198831 - Nitrosylation of protein sh groups and amino acid residues as a therapeutic modality: Nitrosylation of proteins and amino acid groups enables selective regulation of protein function, and also endows the proteins and amino acids with additional smooth muscle relaxant and platelet inhibitory capabilities. Thus, the invention relates to novel compounds achieved by nitrosylation of protein thiols. Such compounds include: S-nitroso-t-PA, S-nitroso-cathepsin; S-nitroso-lipoprotein; and...

20060198830 - Ubiquinone composition and a container for its convenient transport and storage: The present invention relates to a combination of a hermetically sealed, substantially air-tight container, and a quinone-containing composition disposed therein. The container of the present invention is adapted for the convenient transport, and storage of an effective amount of an active ingredient, for example, ubiquinone, ubiquinol or a mixture thereof,...

20060198832 - Peptide drugs for chronic lymphocytic leukemia (cll) and other cancers: The present invention provides a modified BAD peptide or peptidomimetic which includes an amino acid sequence having at least 60% amino acid identity with SEQ ID NO: 1, where the modified BAD peptide or peptidomimetic has enhanced affinity for Bcl-2 as compared to wild type BAD peptide (SEQ ID NO:...

20060198833 - Compositions and methods for targeting a polypeptide to the central nervous system: The invention provides a chimeric CNS targeting polypeptide having a BBB-receptor binding domain and a payload polypeptide domain. The chimeric CNS targeting polypeptide can have a BBB-receptor binding domain consisting of a receptor binding domain from ApoB, ApoE, aprotinin, lipoprotein lipase, PAI-1, pseudomonas exotoxin A, transferrin, α2-macroglobulin, insulin-like growth factor,...

20060198834 - Chaperonin 10 immunosuppression: The invention is directed to the use of cpn10 in transplantation and particularly to treatment and/or prevention of graft versus host disease. The invention provides a method of administration of cpn10 to a donor and/or recipient animal or cells, tissues or organs derived from the donor, although in a particularly...

20060198835 - Nucleic acid molecules encoding osteogenic proteins: Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth in mammals using the devices; 2) amino acid sequence data, amino acid composition, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, 3) methods of producing osteogenic proteins using...

20060198837 - Coagulation and fibrinolytic cascades modulator: A thromboplastin reagent comprises (i) TF, (ii) a phospholipid, and (iii) a polyP TFPI blocker....

20060198836 - Method of treating hit patients with argatroban: This invention relates to the improved methods of use of Argatroban in heparin-induced thombocytopenia....

20060198838 - Combination enzyme for cystic fibrosis: A stable preparation of digestive/pancreatic enzymes which can be readily formed into a dosage formulation is provided as a treatment of pancreatic insufficiency in persons having cystic fibrosis. The dosage formulation can be administered either by an oral preparation including, but not limited to, a microcapsule, mini-capsule, time released capsule,...

20060198839 - Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions: Type 1 diabetes mellitus and other conditions relating to inadequate insulin or diminished levels of insulin can be treated by administering a pancreatic islet cell regeneration agent and/or an agent that transforms pancreatic ductal cells to islet cells in combination with administration of an agent that selectively inhibits, blocks, or...

20060198840 - Molecules with extended half-lives, compositions and uses thereof: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant...

20060198841 - Drosophila g protein coupled receptors, nucleic acids, and methods related to the same: The present invention provides Drosophila melanogaster GPCR (DmGPCR) polypeptides and polynucleotides which identify and encode such a DmGPCR. In addition, the invention provides expression vectors, host cells, and methods for its production. The invention also provides methods for the identification of homologues in other species and of DmGPCR agonists/antagonists useful...

20060198842 - Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors: Screening methods for identifying compounds that bind to or activate corticotropin releasing factor2 receptors (CRF2R) and regulate or potentially regulate skeletal muscle mass or function in vivo are disclosed. Also disclosed are screening methods for identifying compounds that prolong or augment the activation of CRF2Rs or of CRF2R signal transduction...

20060198844 - Bone morphogenetic protein-2 in the treatment and diagnosis of cancer: The present invention pertains to the use of BMP-2, which is overexpressed in most common cancers, as 1) a target for cancer treatment therapies and 2) a means to diagnose cancer. The therapeutic component of this invention involves administering to a patient a composition that inhibits bone morphogenetic-2 activity. Such...

20060198843 - Treatment with anti-erbb2 antibodies and chemotherapeutic agents: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and chemotherapeutic agents....

20060198846 - Combinations for the treatment of diseases involving angiogenesis: Compositions for the inhibition of the formation of new vasculature by angiogenesis are provided comprising the combination of a vasculature damaging agent and an inhibitor of the formation or action of nitric oxide in mammalian systems. There are also provided the use of said combinations in medicaments and kits of...

20060198847 - Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis: A method of modulating angiogenesis in a vertebrate subject, the method comprising administering to the vertebrate subject an ECRTP/DEP-1 activity-modulating amount of a composition, whereby an ECRTP/DEP-1 within the vertebrate subject is contacted by the composition; and modulating angiogenesis through the contacting of the ECRTP/DEP-1 with the composition. Optionally, the...

20060198845 - Monoclonal antibody against human hepatoma and use thereof: The present invention provides a monoclonal antibody MF4C4 against human hepatoma marker antigen. This monoclonal antibody is characterized by high specifically binding to the hepatoma antigen. The present invention also provides MF4C4 immunoglobulins, and the fragments and immunological conjugates thereof, and pharmaceutical compositions containing the immunoglobulins, fragments or immunological conjugates....

20060198848 - Methods and compositions for treating herpes infections: A method of treatment or prophylaxis of herpes infections and associated disease states by administration of compositions comprising immunoglobulins. Methods comprising intravenous and topical administration of immunoglobulins are provided....

20060198849 - Preparation method of igy for preventing and cure mouth disease and the toothpaste base on the igy: The present invention relates to a preparation method of IgY for preventing and cure mouth disease, and a safe toothpaste containing the IgY....

20060198850 - Pharmaceutical formulation and a method of making same: The methods of the present invention and the formulations made from those methods, allow the stable integration of multiple actives within a single formulation. The solubilisation of an active in a suitable solvent and the subsequent adsorption onto a sorbing medium provide effective protection for the active from any adverse...

20060198851 - Humanized abeta antibodies for use in improving cognition: The invention provides improved agents and methods for treatment of diseases associated with beta amyloid (Aβ). Preferred agents include antibodies, e.g., humanized antibodies specific for Aβ....

20060198852 - Collagen-binding mscramms of bacillus anthracis and uses therefor: The present invention provides cell wall anchored proteins of Bacillus anthracis representative of the MSCRAMM family of proteins and DNAs encoding the same. Also provided are collagen-binding peptides comprising the collagen-binding region A of the cell wall anchored proteins and DNAs encoding these peptides. Further provided are pharmaceutical compositions and...

20060198853 - Papilloma virus capsomere vaccine formulations and methods of use: Vaccine formulations comprising viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed....

20060198854 - Vector platforms derived from the alphavirus vaccines: Nucleic acid molecules and vector platforms derived from human virus vaccines, for example the alphavirus vaccines, including the TC-83 human vaccine, are disclosed. These vector platforms can provide for expression of a heterologous protein or nucleic acid in animal or human cells. In preferred embodiments, the nucleic acid molecules and...

20060198855 - Uses of dc-sign and dc-signr for inhibiting hepatitis c virus infection: This invention provides a method of inhibiting HCV infection of a cell susceptible to HCV infection which comprises contacting the cell with an amount of a compound effective to inhibit binding of an HCV envelope glycoprotein to a DC-SIGN protein present on the surface of the cell, so as to...

20060198856 - Ibuprofen suspension stabilized with docusate sodium: A stabilized aqueous pharmaceutical ibuprofen composition of ibuprofen stabilized with a stabilizing effective amount of docusate sodium....

20060198859 - Compositions with a depot effect for controlling microorganisms: The invention relates to compositions for controlling microorganisms comprising an effective content of mixtures of fatty acid esters of a polyol and of short-chain monocarboxylic acids and/or salts thereof....

20060198861 - Flexible ultra-low permeability transport system and method: A system and method for long-term storage of a commodity in a weight range of 10-2000 kilograms includes hermetic sealing of an ultra-low permeability, easily transportable, flexible long-term storage container. The long-term storage container may also be treated using non-toxic insect repellents of botanical origin or using a synthetic pyrethroid....

20060198857 - Insect control system: A system for controlling insects, which system includes a substrate in the form of an elongate tape having thereon a plurality of target zones spaced apart at predetermined intervals along a first surface of the substrate, each target zone including an insect attractant and/or an insect control agent....

20060198860 - Synergistic blends of monoterpenes for mountain pine beetle pheromones: This invention relates to compositions and methods of using blends of two or more monoterpenes as synergists for attractive pheromones of the mountain pine beetle, Dendroctonus ponderosae. When deployed in effective amounts in traps, on pine trees or in the vicinity of pine trees, these blends will increase the numbers...

20060198858 - System and method for effectively controlling household allergens: A system and method of effectively controlling household allergens or pests such as house dust mites or bed mites. The system comprises a container fluidly coupled to a covering, wherein the covering surrounds the household pests' environment. The method for effectively controlling the household pests comprises: surrounding or coupling a...

20060198862 - Snail baiting agent: in which R stands for C1-C10 alkyl, which is equally or differently substituted once or several times by PO3H2, OH, NH2, CN, halogen, C1-C8 alkylamine or C2-C16 dialkylamine and is optionally interrupted by 1-6 heteroatoms from the series N, O, S, P, wherein heteroatoms are not directly coupled to one...

20060198864 - Biointerface membranes incorporating bioactive agents: A biointerface membrane for an implantable device including a nonresorbable solid portion with a plurality of interconnected cavities therein adapted to support tissue ingrowth in vivo, and a bioactive agent incorporated into the biointerface membrane and adapted to modify the tissue response is provided. The bioactive agents can be chosen...

20060198863 - Ceramic composition for filling bone defects: The invention is directed toward a formable ceramic composition for application to a bone defect site which comprises a ceramic compound of beta tricalcium phosphate particles. The particle size ranges from about 40 microns to 500 microns and is mixed in a hydrogel carrier containing citric acid buffer, the hydrogel...

20060198865 - Microencapsulated compositions for endoluminal tissue engineering: A tissue engineering composition adapted for application to an interior surface of a body lumen of a patient. The composition comprises (a) a carrier medium that is adapted to flow and to stably adhere the composition to the body lumen and (b) microcapsules, which are dispersed within the carrier medium...

20060198866 - Thermoplastic fluoropolymer-coated medical devices: A medical device provided with at least a partial surface coating of a thermoplastic copolymer of tetrafluoroethylene and perfluoroalkylvinylether that is free of cross-linking monomers and curing agents. The fluoropolymer coating is preferably an amorphous thermoplastic, is highly inert and biocompatible, has elastomeric characteristics that provide desirable mechanical properties such...

20060198869 - Bioabsorable medical devices: A medical device that is at least partially formed of a bioabsorbable metal alloy that includes a majority weight percent of magnesium and at least one metal selected of calcium, rare earth metal, yttrium, zinc, and/or zirconium....

20060198868 - Biodegradable coating compositions comprising blends: The invention provides devices for treatment of a patient, wherein at least a portion of the device is provided with a biodegradable coating composed of a blend of bioactive agent and at least two biodegradable polymers or copolymers. The invention further provides methods of treatment utilizing the devices....

20060198867 - Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy: Systems and compositions comprising zotarolimus that are safer, more effective and produce less inflammation than rapamycin and paclitaxel systems are disclosed. Medical devices comprising supporting structures capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient can contain one or more therapeutic agents or substances,...

20060198870 - Medical devices containing rapamycin analogs: s

20060198871 - Methods for treating neovascularization and intravitreal implants: Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer....

20060198872 - Plant based dietary supplement for improving the duration and quality of sleep: The present invention relates to compositions for treating insomnia or sleeplessness. The compositions of the present invention comprise jujube extract and at least one of white peony extract, radix polygala extract, and passion flower extract. The extracts used in the compositions of the present invention bind strongly to GABA receptors...

20060198876 - Aqueous disinfectants and sterilants and related delivery systems: The present invention is drawn to disinfectant or sterilant compositions and associated methods of use. In one embodiment, an aqueous disinfectant or sterilant composition can comprise an aqueous vehicle, including water, from 0.001 wt % to 50 wt % of a peracid, and from 0.001 wt % to 25 wt...

20060198875 - Core assembly for essential oil: A core assembly for essential oil includes an oil suction member, and a core head mounted on and connected to a top end of the oil suction member. Thus, the core head is combined with the oil suction member, so that the essential oil absorbed by the capillary effect the...

20060198877 - Medical instrument for autologous chondrocyte transplantation: A medical instrument for autologous chondrocyte transplantation comprises a stamp for introducing an implantable nonwoven into a cartilage. This stamp has, on a distal end face, at least one opening to which an underpressure can be applied....

20060198873 - Orally dissolving films: Rapidly dissolving, oral film preparations for rapid release of an active agent in the oral cavity, in particular, rapidly dissolving oral films comprising a nicotine active which achieve good transbuccal absorption and provide nicotine craving relief to an individual are disclosed herein....

20060198878 - Preparation in film form for biphasic release of pharmaco-logically active or other substances: A polymer-based preparation in film form for biphasic release of substances present therein to liquid surroundings, is characterized in that the preparation comprises at least two polymer matrix layers which differ in terms of their construction from polymers, with release taking place rapidly from one of the layers, and release...

20060198874 - Warming and cooling devices made of hypoallergenic organic materials: Therapeutic devices for warming and/or cooling limbs, joints, and body parts, to relieve pain or discomfort, are made of entirely hypo-allergenic materials, such as organically grown cotton fabric and flaxseed. Flaxseed can be heated effectively and safely in a microwave oven, and has a relatively high “specific heat”, allowing it...

20060198879 - Patch material for ionic medicine administration: The present invention discloses a patch for use in administration of an ionic medicine into a living body by infiltration of the ionic medicine into the living body through the living body surface without voltage application, characterized in that the patch comprises an ion-exchange membrane having a surface roughness (Rz)...

20060198880 - Ultraviolet-shielding type patch: e

20060198881 - Tamper resistant transdermal dosage form: The invention comprises a transdermal dosage form comprising an active agent component comprising an active agent and an adverse agent component comprising an adverse agent, wherein the active agent component defines at least one channel extending substantially there through....

20060198882 - Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer: The present invention concerns a stable lipid assembly comprising a biologically active lipid having a hydrophobic region and a polar headgroup, wherein the atomic mass ratio between the headgroup and hydrophobic region is less than 0.3, and a lipopolymer having a hydrophobic lipid region and a polymer headgroup, wherein the...

20060198883 - Compositions and methods for the treatment of anorectal disorders: Compositions and methods for the treatment of anorectal disorders are provided in which certain combinations of NO donors, PDE inhibitors, superoxide (O2−) scavengers, β-adrenergic agonists, cAMP-dependent protein kinase activators, α1-adrenergic antagonists, L-type Ca2+ channel blockers, estrogens, ATP-sensitive K+ channel activators and smooth muscle relaxants are used....

20060198884 - Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane: The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following...

20060198885 - Oral pharmaceutical composition: An oral pharmaceutical composition having reduced bitterness comprising therapeutically effective amounts of cetirizine or its pharmaceutically acceptable salts, alkaline earth oxide and a pharmaceutically acceptable carrier comprising a disintegrant wherein the composition disintegrates rapidly in the oral cavity....

20060198887 - Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof: An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch....

20060198886 - Medicament having coated methenamine combined with acidifier: A solid pharmaceutical medicament has a coated methenamine compound in combination with an urinary acidifier....

20060198888 - Tolperisone-containing pharmaceutical preparation with controllable active-substance release for oral administration: The invention relates to a tolperisone-containing pharmaceutical preparation with controllable active-substance release for oral administration, characterised in that the active substance tolperisone and/or a pharmaceutical salt thereof is embedded in a pharmaceutically compatible material. By selecting the pharmaceutically compatible materials in the preparation and accordingly in the coating of a...

20060198889 - Roflumilast and integrin inhibitor combination and treatement method: The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a therapeutically active amount of roflumilast, or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of N-(2-chloro-6-methylbenzoyl)-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine-2-(diethylamino)ethyl ester, or a pharmaceutically acceptable thereof, and one or more pharmaceutically acceptable excipients. These novel solid pharmaceutical dosage forms...

20060198890 - Durable film coating compositions having sustained slow-release capability, and methods of use therefor: Provided is a slow-release delivery vehicle for delivering at least one active ingredient into a film coating, comprising a population of stable, homogeneously-dispersed, porous polymeric or co-polymeric beads having a network of pores, wherein the at least one active ingredient is held within the bead particles and within the network...

20060198892 - Polymeric systems for controlled drug therapy: Polymeric compositions containing a high percentage of bound alkyl ether segments provide matrices and membranes for the controlled release of drugs and medicinal agents. The polymeric compositions are prepared by the polymerization of ethylenically unsaturated alkyl ether containing monomers. Copolymers of ethylenically unsaturated alkyl ether containing monomers with co-monomers are...

20060198891 - Solid formulations of liquid biologically active agents: The instant invention relates to a solid product comprising a liquid biologically active agent which is intimately associated to a stabilizing agent; particularly a solid product that can be reconstituted to a clear, stable, stabilized nanodispersion or loaded micelles comprising a polymer as a stabilizing agent and a liquid, preferably...

20060198896 - Aerosol and injectable formulations of nanoparticulate benzodiazepine: Described are nanoparticulate formulations of a benzodiazepine, such as lorazepam, that does not require the presence of polyethylene glycol and propylene glycol as stabilizers, and methods of making and using such formulations. The formulations are particularly useful in aerosol and injectable dosage forms, and comprise nanoparticulate benzodiazepine, such as lorazepam,...

20060198893 - Aqueous dispersion comprising stable nanoparticles of a water-insoluble pyrrole carboxamide and excipient like middle chain triglycerides: s

20060198895 - Azithromycin powder for oral suspension compositions: Non-caking azithromycin powder for oral suspension compositions and methods of making such compositions are disclosed. The compositions comprise a hydrated buffer, preferably a hydrate of sodium phosphate such as tribasic sodium phosphate dodecahydrate....

20060198894 - Stabilized, solid-state polypeptide particles: The present invention includes solid-state polypeptide particles containing a polypeptide material that is stabilized against degradation at temperatures that approximate or exceed physiological conditions. In each embodiment, the polypeptide particles of the present invention incorporate a polypeptide material that is stabilized against degradation by one or more stabilizing conditions. Because...

20060198897 - Polycationic peptide coatings and methods of coating implantable medical devices: Coatings for medical devices which include polycationic peptides such as L-arginine and methods for fabricating the coatings are disclosed....

20060198898 - Method for preventing ulceration or irritation of mucosa: The present invention provides novel compositions and methods for protecting and promoting cell growth and restoring physiological structure and function to mucosal tissue of the body, especially mucosa in the gastrointestinal tract. The composition can be used as a pharmaceutical or nutraceutical to treat a gastrointestinal disorder or to promote...

20060198900 - Bioactive agent compositions for repair of cell injuries: A method for prophylactically treating a gastrointestinal disorder or skin ailment in a mammal through the administration of an enhanced bioactive agent composition comprising a bioactive agent and at least one of a soy product, licorice product, or sodium bicarbonate (depending upon the indication to be treated) is provided according...

20060198899 - Supplemental dietary composition for supporting muscle growth, recovery and strength: Methods and compositions for the purposes muscle growth, recovery and/or strength are set forth. The compositions may include, but are not limited to, creatine monohydrate, glutamine alpha-ketoglutarate, glutamine, glutamine peptides, L-glutamine, L-leucine, L-valine, L-isoleucine and guar gum. The supplemental dietary compositions may be suitable for persons seeking to improve strength...

20060198901 - Drugs, bio-affecting and body treating compositions: Micro-clustered water compositions of bio-affecting agents, body-treating agents, and adjuvants or carriers, pharmaceutical and diagnostic compositions thereof. Methods of using the compositions involving administering them ex vivo to cells, tissues or organs, or in vivo to living bodies; and methods of making the compositions....

20060198903 - Antimicrobial coating methods: The invention is directed to efficient methods for depositing highly adherent anti-microbial materials onto a wide range of surfaces. A controlled cathodic arc process is described, which results in enhanced adhesion of silver oxide to polymers and other surfaces, such as surfaces of medical devices. Deposition of anti-microbial materials directly...

20060198902 - Topical medicament and method of use: A topical medicament, and associate method of use, for the treatment of dermatologic conditions in both humans and animals is provided. The medicament includes a mixture of Vitamin A, Vitamin D, Vitamin E, lanolin, petroleum jelly, colloidal silver, ti tree oil, zinc oxide and corn starch in appropriate proportions. Ingredient...

20060198906 - Compositions and method to increase serum levels of hdl cholesterol and lower the risk of cardiovascular disease: The invention provides a method for increasing serum high density lipoprotein (HDL) cholesterol levels, and lowering serum levels of Lipoprotein (a) and C-reactive protein, as well as a suitable composition comprising a) a vegetable protein, b) a natural antioxidant compound, c) a natural anti-inflammatory compound, d) a bioavailable source of...

20060198904 - Methods for inhibiting allergic inflammation and other responses initiated by pollens, molds, and other non-animal derived allergens: Disclosed are methods for treating or preventing allergic inflammation in a subject and methods for treating or preventing one or more symptoms of allergic inflammation in a subject. The methods include administering to the subject a compound which inhibits reactive oxygen species. Also disclosed are methods for reducing a non-animal-derived...

20060198905 - Pharmaceutical compositions comprising an extract of euphorbia prostrata: The invention relates to novel compositions comprising of an extract of the plant Euphorbia prostrata, particularly with pharmaceutically acceptable carrier(s)/base(s), optionally with additional therapeutic agent(s) useful for the treatment of anorectal disease and colonic diseases such as hemorrhoids, fissures, cracks, fistulas, abscesses, inflammatory bowel disease, and the like. The nove(...

20060198907 - Pharmaceutical, therapeutic, and dietary compositions derived from lagerstroemia speciosa l. plant: The present invention relates to pharmaceutical, therapeutic, and dietary compositions derived from leaf of the Lagerstroemia speciosa L. plant and the novel extraction processes used to produce these controlled blends of varying composition with respect to corosolic acid, gallotannins, ellagitannins, and valoneic acid dilactone. Embodiments of the invention include an...

20060198908 - Ginseng preparation using vinegar and process for thereof: The present invention relates to a ginseng preparation using vinegar and a process for preparing the same, more particularly to a ginseng preparation comprising high concentrations of ginsenosides (Rg3, Rg5, and Rh1), which are generated by heat and exist only small amounts in red ginseng comprising various organic acids of...

20060198909 - Process to lose weight, drain unwanted body fats and other toxins: A method is disclosed comprising placing about thirty-two fluid ounces of water into a receptacle, placing the receptacle with water on a burner and bringing the water to a boil, ceasing to heat the water, adding about one teaspoonful or five grams of tea beverage flavorant to the water; and...

20060198910 - Method for processing vegetable raw materials: The inventive method for processing vegetable raw materials consisting in organic solvent-extracting said materials, isolating it by retention which is associated with cooling and wax filtration, separating free oxides from the thus obtained solution of extractive substances by alkali solution action, dividing the obtained neutralised solution into a neutral substance...

20060198911 - Foodstuff produced with extract of peanut stem for regulating blood sugar: A foodstuff is produced through extracting healthful and medicinal compositions contained in peanut stems. The food stuff may be in the form of liquid, cream, powder, tablet or capsule for users to drink, eat, or swallow conveniently. The foodstuff produced with extract of peanut stem contains not only nutrient that...

20060198912 - Topical treatment compositions: A dermatological treatment composition that includes an oil extract of leleshwa. The oil extract of leleshwa can be used alone or combined together with other ingredients in liquid, ointment, salve, gel, cream or foam formulations to treat a variety of dermatological conditions, including athlete's foot, verruca, shingles, atopic dermatitis, and...

20060198913 - Method of improvement of blood circulation: A method for the enhancement of the blood microcirculation and/or the oxygen supply of the skin of the lower extremities in a patient in need thereof, which method comprises administering an effective amount of an aqueous extract of red vine leaves to the patient....

20060198914 - Use of rutin and isoharmnetin for treating depressive states and depression and other emotion disorders: The present invention relates to the use of rutin and isorhamnetin for the treatment of episodes of depression and depressive diseases as well as in case of other affective disorders and preliminary stages thereof....